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                             General Introduction: Statement of the Problem 
 
Alterations in intestinal homeostasis: Inflammatory bowel disease    
Maintenance of intestinal homeostasis in the context of a diverse and abundant 
intestinal bacterial flora is a complex process that requires coordination between multiple 
components of the adaptive and innate immune system and elements of the mucosal 
barrier.[1]  Failure of the innate immune response, such as a primary defect in intestinal 
macrophages, or, for example, a breakdown of mucosal barriers following injury to 
enterocytes can potentially serve as a catalyst for initiating chronic, adaptive immune 
response mediated inflammation.[2, 3] Furthermore, infection with, or exposure to, microbial 
pathogens can cause a shift in this regulatory network and tip the balance in favor of 
inflammation, with the potential to exacerbate pre-existing inflammation in disorders of 
chronic inflammation, such as inflammatory bowel disease (IBD).[4] 
Chronic inflammation with disruption of intestinal homeostasis is the hallmark lesion 
in both of the distinct clinical phenotypes of the inflammatory bowel diseases, Crohn’s 
disease (CD) and ulcerative colitis (UC).[5] The pathogenesis of these disorders is thought to 
be multifactorial, with environmental factors, deregulation of the host immune response, the 
normal intestinal flora, and the genetic background of the host all considered being important  
factors that interact to result in the characteristic clinical and pathologic features of these 
diseases.[6]  Although defects in these broad categories are thought to be essential for the 
manifestation of the inflammation observed in IBD, the precise casual mechanisms leading to 
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the initiation of inflammation of these disorders is not understood, and, more specifically, it 
is not completely clear how or if functional alterations in components of the innate immune 
system, such as intestinal macrophages, contribute to pathogenesis of IBD.  
Intestinal macrophages as key effectors in maintaining intestinal homeostasis: 
Intestinal macrophages play a critical role in maintaining mucosal homeostasis.[7] 
Therefore, it is essential to understand how changes in macrophage phenotype, secondary to 
infections or genetic mutation, alters the microenvironment of the intestine and whether or 
not these changes influence the susceptibility of the host to subsequent intestinal injury. With 
respect to their homeostatic role, resident intestinal macrophages have a unique functional 
phenotype. They can eliminate potential pathogens while at the same time preventing 
harmful inflammation.[8] This anti-inflammatory phenotype of human intestinal 
macrophages is defined by the absence of innate response receptors such as receptors for LPS 
(CD14) and CR4 (CD11c/CD18) and the inability to produce pro-inflammatory cytokines in 
response to inflammatory stimuli.[8] Despite this dual protective role of intestinal 
macrophages, it is clear that they can contribute to the pathogenesis of mucosal injury, such 
as in IBD where it has been documented that large amounts of IL-1β are produced almost 
exclusively by intestinal macrophages.[9, 10] Although these studies demonstrate that 
intestinal macrophages have important homeostatic or potentially pathogenic roles in the 
intestinal mucosa, there is a gap in our knowledge about the ability of a chronic intestinal 
infection of macrophages to cause a shift in macrophage effector function which 
subsequently impairs the host response to mucosal injury.  
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The influence of microbial pathogens on intestinal homeostasis: 
Experimental studies in which colitis does not develop in germ-free mice indicates 
that the normal intestinal flora plays an important, if not essential, role in the development or 
maintenance of intestinal inflammation.[11] Some studies suggest that this may represent a 
type of autoimmune response since neonatal rats colonized by bacteria develop tolerance to 
bacterial antigens, presumably due to intra-thymic processing that causes the host to 
recognize the bacteria “self” antigens.[12] Although these reports highlight the importance of 
the intestinal flora in experimental models of IBD, the significance of any single infectious 
agent is questionable. Several epidemiologic studies and animal models of IBD suggest that 
microbial pathogens may have a role in initiating or exacerbating pre-existing inflammation 
in IBD.  The most convincing support for the role of a specific intestinal pathogen in IBD has 
been demonstrated in patients with ileal CD, where an increased number of patients are 
colonized by an adherent/invasive strain of E. coli (AIEC).[13] It has been reported that 
AIEC was recovered from 36% of mucosal biopsy specimens from patients with early 
postresection recurrent CD relative to 6% of normal control ileal biopsy specimens.[14, 15] 
This strain of E. coli is able to both replicate and persist within macrophages and enhance 
macrophage secretion of TNF-α.[16] Experimentally, superimposed exposure to low-level 
microbial pathogens can exacerbate intestinal inflammation.  For example, exacerbation of 
chemically mediated intestinal inflammation has been shown following acute luminal 
exposure to Bacteroides fragilis, AIEC, and Hymenolepis diminuta.[17-19] These studies 
emphasize the potential for microbial infections to alter intestinal mucosal homeostasis and 
the need to further define the mechanisms associated with microbe induced disturbances in 
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intestinal inflammation. In a broader sense, since large numbers of macrophages in the 
intestine are strategically placed in the lamina propria adjacent to abundant numbers of 
immunostimulatory bacteria, it is imperative to understand how infections of intestinal 
macrophages affects their function, in particular, their response following exposure to the 
normal flora or its products.         
 This literature review will focus on components of the intestinal mucosal barrier, with 
an emphasis on macrophages in the context of IBD and how infections with low level 
pathogens, and to a lesser extent non-microbial factors, may cause a positive or negative shift 
in the response of the mucosa to injury.    
Specific Aims 
 Our primary goal was to understand how a subclinical intestinal infection with 
Mycobacterium avium ss paratuberculosis (Map) would influence subsequent acute mucosal 
injury. To address this goal, we utilized a mouse model of intestinal Map infection.[20, 21] 
BALB/c mice were infected with Map strain K10 and subsequently administered a low dose 
of dextran sulfate sodium (DSS) in the drinking water to induce mild intestinal injury. Our 
central hypothesis was that persistent intestinal mycobacterial infection sensitizes the host to 
enhanced intestinal injury. The following specific aims were pursued to test this hypothesis: 
1) determine if subclinical intestinal Map infection influences subsequent DSS mediated 
intestinal inflammation (Chapter 2); 2) define how Map infection influences the 
characteristic DSS mediated  intestinal immune profile and determine if Map infected mice 
had a Map-specific immune response (Chapter 3); 3) determine how infection with Map 
5 
 
alters the phenotype and function of intestinal macrophages following injury to the intestinal 
mucosa or in vitro stimulation with LPS (Chapter 4).    
Dissertation Organization 
 This dissertation is organized in the alternative format with the first chapter being a 
general introduction and literature review (Chapter 1). This is followed by three manuscripts 
(Chapters 2-4) which have been prepared for submission to the journal of Experimental 
Biology and Medicine, Clinical and Experimental Immunology, and the Journal of 
Leukocyte Biology, followed by general conclusions. References are cited at the end of each 
chapter. 
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     Chapter One: Literature Review 
Intestinal homeostasis and the role of the mucosal barrier: 
The intestinal mucosal barrier is a complex cellular and biochemical structure that has 
multiple physiologic roles, including nutrient, electrolyte and fluid absorption and, perhaps 
most importantly, it serves to limit and regulate exposure of the host innate and adaptive 
immune system to the abundant bacterial and dietary antigens in the adjacent intestinal 
lumen.[1] This barrier is composed of multiple cell types and their associated secreted or cell 
surface products, such as mucus and tight junctions and whose permeability is influenced by 
interactions with both the contents of the intestinal lumen and the innate and adaptive 
immune cells in the adjacent lamina propria.[2] Given the importance of disturbances in 
intestinal permeability in diseases such as IBD, it is essential to try and understand the 
potential triggers associated with alterations in the mucosal barrier that can initiate or 
promote the characteristic chronic inflammation that is the hallmark of IBD.[3]      
Intestinal permeability and intercellular junctional complexes 
The microbial diversity and bacterial load in the intestinal lumen is large, with 
increasing concentrations of bacteria from the relatively sterile gastric lumen to the large 
intestine which contains up to 1011 to 1012 bacteria per gram in the cecum and colon.[4] 
Enterocytes, mucus and tight junctions all have an essential role in regulating intestinal 
permeability and preventing translocation of these bacterial antigens across the mucosal 
barrier. There are two principal routes by which material can traverse the mucosal barrier. 
One route is transcellular, in which molecules pass directly through epithelial cells, with the 
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other being the paracellular route which is regulated by intercellular junctional complexes 
and allows material to pass between enterocytes.[1] Disruption of the mechanisms regulating 
passage of antigens via these routes can result in increased permeability and passage of 
antigens potentially promoting the development of or maintenance of mucosal 
inflammation.[3, 5, 6] The importance of enhanced intestinal permeability in the 
pathogenesis of IBD is highlighted in studies that have demonstrated familial associated 
increased intestinal permeability in first degree relatives of patients with CD and in a case 
report describing increased intestinal permeability in a patient prior to the development of 
CD.[7, 8] Therefore, it is critical to understand the normal physiology of the mucosal barrier 
and mechanisms associated with maintaining its integrity that prevent unwanted exposure of 
immune cells to luminal bacterial antigens.  
Enterocyte associated intercellular junctional complexes are essential regulators of 
intestinal permeability, with defects in their structure or function predisposing the host to 
intestinal inflammation.[3] Intercellular junctional complexes are cell surface associated 
structures located at the lateral apical and lateral margins of the enterocyte and include tight 
junctions, adherens junctions, and desmosomes.[9] These structures are composed of 
transmembrane proteins which are linked to the intracellular actin cytoskeleton and relative 
to the adherens junctions and desmosomes, which are thought to be primarily responsible for 
the mechanical linkage between adjacent cells; the tight junctions have an additional role in 
selectively regulating paracellular ion transport.[10-14]  
The major structural components of the adherens junctions include the 
transmembrane glycoprotein E-cadherin that is bound intracellularly to catenin proteins. The 
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catenins, in turn, link the adherens junction complex to the intracellular cytoskeleton.[11] 
The adherens junctions not only function in physically linking adjacent cells, cadherin-
catenin complexes also have an important role in forming desmosomes, proliferation and 
migration.[15, 16] The importance of the cadherins in intestinal homeostasis is highlighted in 
a study where mouse enterocytes containing a dominant negative N-cadherin mutation. This 
resulted in alterations in the rates of cell migration and programmed cell death and the 
development of intestinal inflammation.[17]   
In contrast to the adherens junctions, the tight junctions are composed of four 
different transmembrane proteins, including claudins, occludin, tricellulin, and junctional 
adhesion molecules (JAMs), with the functional integrity of the tight junction complex being 
modulated by phosphorylation of these proteins.[18-20] Similar to the transmembrane 
proteins of the adherens junction, proteins of the tight junction, such as occludins and 
claudins are linked to the cytoskeleton via a distinct group of proteins, the zonula occludens 
(ZO).[21, 22] Alterations or loss of proteins of the tight junction such as ZO-1 and JAM-A 
can result in increased permeability leading to translocation of luminal bacterial antigens. An 
example of which occurs following treatment of mice with DSS.[23] This change in ZO-1 
presumably occurs before the development of inflammation and is not a consequence of the 
intestinal inflammation induced by DSS treatment.  Although individual proteins of the tight 
junction have an important role in adhesion and paracellular permeability, the absence of a 
single component of the complex does not always result in a dysfunctional phenotype as 
demonstrated in mice lacking occludin which still have normal tight junction formation, 
numbers, and barrier function.[24]   
11 
 
Further support for the importance of enterocytes and their associated intercellular 
junctional complexes in maintaining the mucosal barrier is provided by numerous animal 
models that have elucidated diverse mechanisms that can promote intestinal permeability. 
For example, in IL-10 knockout mice, increased enterocyte apoptosis can be induced by 
treatment with a non-steroidal anti-inflammatory drug such as piroxicam, resulting in 
increased permeability and inflammation secondary to exposure to the normal flora in the 
intestinal lumen.[25] Furthermore, different cytokines such as TNF-α and IFNγ can directly 
enhance the permeability of the intestinal mucosa by interfering with the integrity of the tight 
junction complexes. For instance, IFNγ can increase paracellular permeability by promoting 
the disassembly of the tight junction proteins via a macropinocytosis or an endocytosis 
mediated mechanism that involves a Rho-associated kinase.[26, 27] With respect to TNF-α 
mediated alterations of the tight junction, in vitro incubation of intestinal epithelial cells with 
increasing concentrations of TNF-alpha can cause a decrease in claudin-1 which was 
speculated to be associated with relocation of ZO-1.[28] It has also been demonstrated that 
these two cytokines can synergistically act to alter the intestinal epithelial barrier by 
increasing the expression of  myosin light chain kinase (MLCK) with phosphorylation of 
myosin II regulatory light chain (MLC).[29] The phosphorylation of MLC promotes opening 
of the tight junction via contraction of peri-junctional actin-myosin filaments.[30-32] 
Moreover, another innate cytokine, namely IL-1β, is capable of altering tight junctions by a 
similar mechanism. It does so via activation of NF- κβ, resulting in an increase in the 
expression of myosin L chain kinase.[33, 34] 
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The role of enterocytes in the mucosal barrier:   
Enterocytes are the initial cellular component of the host that provides not only a 
physical barrier to the luminal bacterial antigens but they also participate in a dynamic 
interaction with the intestinal flora to either promote or inhibit the inflammatory response. A 
key molecule in determining whether or not an inflammatory response will occur following 
interaction with the intestinal flora is NF- κβ. For example, by way of TLR2 and TLR4, 
colonic epithelial cells in germ-free mice colonized with either Bacteroides vulgatus or 
Enterococcus faecalis respond to this interaction with temporary NF- κβ activation, with 
perpetual activation of NF- κβ being associated with deficiency of IL-10 as shown in mice 
monoassociated with Enterococcus faecalis.[35, 36] In addition to IL-10, NF- κβ signaling is 
thought to be modulated by lamina propria derived TGF-β, as suggested by increased SMAD 
signaling and corresponding decreased NF- κβ activation following bacterial colonization of 
intestinal epithelial cells.[36]  
The NF- κβ pathway can also be differentially influenced by the properties of the 
stimulating microbe. For instance, pathogenic and non-pathogenic intestinal bacteria are 
capable of either activating or suppressing this key nuclear transcription factor. In a polarized 
model of intestinal epithelial cells, it has been shown that the pathogen Salmonella 
typhimurium activates Iκβα kinase in a Ca2+ dependent manner resulting in the translocation 
of NF- κβ. This ultimately results in the production of the neutrophil chemoattractant IL-
8.[37] In contrast, it has been shown, again with a polarized model of human epithelia, that a 
non-virulent strain of Salmonella is capable of inhibiting Iκβα degradation which prevents 
activation of the Iκβ/NF- κβ. This is accomplished by preventing polyubiquination of Iκβα, 
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thus it avoids degradation by the proteasome.[38] In addition to the different pathogenic 
properties of a particular bacterium influencing the activation of NF- κβ, the spatial location 
of TLRs can influence whether or not NF- κβ will be activated; even with the same TLR. In 
the case of TLR9, which has both apical and basolateral expression in enterocytes, 
stimulation of the basally located TLR9 results in activation of NF- κβ due to Iκβα 
degradation. However, NF- κβ activation is prevented if apical TLR9 is activated which 
causes accumulation of ubiquinated Iκβα.[39]  
NF- κβ appears to have opposing functions in the intestine. In addition to its well-
documented pro-inflammatory properties, NF- κβ has a seemingly contradictory protective 
role in maintaining the integrity of the intestinal mucosa. One example of this protective 
effect was demonstrated in mice which develop spontaneous colitis following conditional 
deletion of Iκβ-kinase γ (Iκκγ-NEMO), which is necessary for NF- κβ signaling, in their 
intestinal epithelial cells.[40]  Protective mechanisms associated with NF- κβ signaling 
include both functions in epithelial repair and secretion of products that alter the immune 
response. For example epithelial NF- κβ can promote repair of epithelial damage, as 
demonstrated in a mouse model of defective TLR signaling where there is decreased mucosal 
hyperplasia in conjunction with bacteremia and the production of type 1 interferons.[41]  
Intestinal epithelial secreted products such as thymic stromal lymphopoietin (TSL) 
are capable of dampening chronic intestinal inflammation by inhibiting dendritic cell 
production of IL-12/23.[42] Moreover, TSL may be associated with suppression of pro-
inflammatory cytokines such as IL-1β or altering the development of intestinal macrophages. 
This is based on studies indicating TSL functions to limit inflammation in a mouse model of 
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DSS mediated intestinal inflammation and the suggestion by some author’s that it may be 
involved in the phenotypic maturation of intestinal macrophages.[43-45] These studies 
emphasize that enterocytes are not restricted in only acting as a physical barrier but also are 
participants in a dynamic relationship with the overlying microflora in the intestinal lumen.    
Intestinal mucus: 
 Intestinal goblet cell produced mucus is a component of the mucosal barrier that 
perhaps gets overlooked compared to disturbances in the mucosal immune system in the 
pathogenesis of IBD.[46] However, several studies in patients with IBD demonstrate 
alterations in this protective barrier. Reductions in goblet cell numbers and a corresponding 
thinning of the mucus layer have been described in patients with IBD.[46] Moreover, another 
study demonstrated that approximately 40% of patients with IBD had anti-goblet cell 
autoantibodies.[47]  
   Intestinal mucus is an O-glycosylated, carbohydrate rich material that contains 
proteins such as Muc2 and Muc3 whose expression within the intestinal tract varies.[48, 49] 
For example, Muc3 is predominantly expressed in the small intestine relative to Muc2 which 
is expressed in both the small and large intestine.[49] Likewise, there are spatial and regional 
differences in how the intestinal microflora interacts with the mucus. For instance, bacteria 
are generally not present in mucus of the distal to mid colon, in contrast to the proximal 
colon and cecum where there may be mucosal and luminal associations of bacteria.[50] 
Therefore, disruption of this delicate barrier may promote the development of mucosa 
associated biofilms, which are present in up to two thirds of patients with IBD, or possibly 
allow opportunistic pathogens to interact with the intestinal epithelium. Experimental 
15 
 
disruption of this barrier, for example in mice deficient in the Muc2 protein, is associated 
with the development of colitis and increased expression of IL-1β and TNF-α.[46] Therefore, 
these studies confirm that intestinal mucus is protective and its absence or thinning may 
allow for the association of bacteria with the mucosa which may serve as a trigger for 
development of intestinal inflammation.  
Normal flora:  
As highlighted in the previous sections, the mucosal barrier plays an important role in 
preventing the normal bacterial flora from gaining access to the mucosal immune system. 
The immensely complex and abundant normal flora can have a profound effect on the 
physiology of the host in terms of their production of various metabolites following 
metabolism of undigested carbohydrates, mucus and exfoliated epithelial cells which can 
influence the immune system, energy balance and epithelial function of the host.[51-53] For 
example, bacteria contain a variety of enzymes that are capable of metabolizing xenobiotic 
compounds and are capable of synthesizing vitamins, short-chain fatty acids and 
methane.[54] Bacterial numbers increase in number from the relatively sterile stomach to the 
densely populated colon, with the proximal intestine containing a greater percentage of 
aerobes compared to the relatively large number anaerobes within the colon.[4]  In total there 
are up to 1013 to 1014 total microorganisms and 15,000 to 36,000 individual species within 
the intestinal tract, with approximately 99% of the bacteria belonging to one of 4 bacterial 
divisions, which are the Proteobaceria, Actinobacteria, Bacteroidetes and Firmicutes.[54-56] 
The Firmicutes, which contain the clostridial XIV and IV groups are the most abundant, with 
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Bacteriodetes accounting for the next largest percentage of bacteria, and the Proteobacteria, 
which includes Escherichia coli, accounting for the smallest number of bacteria.[54]       
  The significance of the normal bacterial flora in experimental models of IBD is 
emphasized by studies where colitis does not develop in germ-free mice.[57] Further support 
for the importance of the intestinal microbial flora in intestinal inflammation is provided by 
the C3H/HeJBir mouse model of spontaneous colitis in which CD4+ T-cells reactive to 
antigens of the normal bacterial flora can cause intestinal inflammation following adoptive 
transfer to SCID mice and based on the observation that antibiotics and probiotics can treat 
or prevent IBD.[58, 59]  
In humans, shifts in the composition of the bacterial flora have been defined in 
patients with UC and CD, but it is not clear if there are disease specific changes relative to 
UC and CD. Frank et al, described alterations in different phyla of bacteria, with decreased 
numbers of Bacteroidetes and  Firmicuties with increases in Actinobacteria and 
Proteobacteria.[56] However, it is not apparent if these changes are a secondary 
phenomenon or involved in the initiation of intestinal inflammation. A bacterial induced 
colonic epithelial nutrient deficiency represents a plausible disease associated mechanism 
following shifts in the composition of the intestinal microflora. For example, the production 
of short chain fatty acids by bacteria of the intestinal microflora serves as nutrient source for 
colonic epithelial cells, with decreased concentrations of short chain fatty acids being 
detected in the patients with IBD.[60] Deficiencies in nutrients could be further 
compounded by alterations in the production of hydrogen sulfide which could interfere with 
the utilization of short chain fatty acids by epithelial cells.[61]   
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The role of opportunistic pathogens in IBD and models of enhanced intestinal inflammation 
Although the normal intestinal flora is an important contributing factor in IBD, the 
significance of any single infectious agent is questionable. The most convincing support for 
the role of a specific intestinal pathogen in IBD has been demonstrated in patients with ileal 
CD, where an increased number of patients are colonized by an adherent/invasive strain of E. 
coli (AIEC) that can persist within epithelial cells and macrophages and has been shown to 
enhance macrophage secretion of TNF-α.[62, 63] AIEC was recovered from 65% and 36% of 
mucosal biopsy specimens from patients with chronically inflamed ileal resections or early 
postresection recurrent CD, respectively, compared to 6% of normal control ileal biopsy 
specimens.[64, 65] The ability of AIEC to colonize the ileum in CD is dependent on the 
expression of a type I pilus which allows adherence to an AIEC induced epithelial receptor 
CEACAM6, the induction of which is mediated by cytokines such as TNF-α and IFNγ.[66] 
Flagellin of AIEC represents another important virulence factor of the LF82 strain of E. coli 
and has been speculated to be essential for AIEC enhanced intestinal inflammation following 
DSS treatment, which is associated with increased expression of IL-1β and IL-6.[67]   
In addition to AIEC, there has also been an association between exposure to 
Mycobacterium avium ss paratuberculosis (Map) and CD.[68] Map is an enteric pathogen of 
adult ruminants that causes chronic weight loss and diarrhea following a prolonged 
incubation period.[69] It is an obligate intracellular pathogen of macrophages, with  a 
characteristic lesion associated with Map  infection being transmural thickening of the 
terminal ileum by a large numbers of macrophages.[69] The belief that Map infection may 
have a role in the pathogenesis of CD has been tenuously extrapolated from the presence of 
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grossly similar lesions seen in patients with Crohn’s disease when compared to the lesions of 
bovine Johne’s disease.[70] Exposure to Map through the food supply may not be a rare 
event; for example, Map has been detected in commercially pasteurized milk, during the 
manufacture and ripening of cheddar cheese, and following sub-pasteurization heat treatment 
of milk used for cheese manufacture.[71-73] Furthermore,  the detection of Map DNA within 
the lesions of Crohn’s patients, the isolation of Map organisms from the blood of patients 
with CD, and the detection of Map antigen specific antibody within the serum of Crohn’s 
patients provides circumstantial evidence that Map plays a role in the pathogenesis of 
Crohn’s disease. [74-79] What is more, an open-label drug trial has been conducted in  
patients with Crohn’s disease in which complete clinical remission was observed following 
treatment with anti-mycobacterial drugs.[80] However, contradictory reports exist on the 
significance of Map in the pathogenesis of CD. For example, some studies have not detected 
Map 16s rRNA in patients with CD or UC; and, even though a subset of CD patients may 
have genetic defects that affect innate immune function; namely, the NOD2 mutation, which 
may predispose patients to an intracellular pathogen such as Map, there is a lack of an 
association between NOD2 polymorphisms and Map infection.[56, 81, 82]   
 Although previous studies provide evidence for an association between Map 
exposure and CD, there is limited experimental data from animal models to support the claim 
that Map infection is essential for the development or maintenance of inflammation in CD. 
Exposure to Map can exacerbate disease in an IL-10 deficient mouse model of spontaneous 
intestinal inflammation.[83] The Map exposed mice in this model had increased weight loss 
and higher colonic lesion scores following oral challenge with Map strain Ben (ATCC 
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43544), with enhanced production of Ag85B/MPT59 peptide 25 specific TNF-α and IFNγ 
from both serum and cells isolated from the Peyer’s patches and mesenteric lymph 
nodes.[83]  The author’s proposed that since Ag85B/MPT59 peptide 25 is conserved across 
several mycobacterial species, that Map may function as an immunomodulator that 
stimulates T-cells in a manner similar to a superantigen, suggesting that the enhanced disease 
observed in these mice is not unique to Map. Several other investigators have also presented 
data suggesting Map may act as a modifying variable in CD patients by functioning as a 
modulator of the immune response, but not in a cause effect relationship with the disease.[84, 
85] In particular, Map exposure in CD patients has been associated with enhanced secretion 
of TNF-α, which is therapeutically important since anti-TNF-α therapy is often effective in 
patients with CD.[86] It is also possible that exposure to or infection with Map promotes 
increased production of IL-1β in a subset of genetically susceptible individuals, for example 
in individuals with a defect in autophagy related killing.[87, 88] Following in vitro infection 
or exposure of bovine and murine macrophages with Map or Map cell wall components there 
is increased production of IL-1β.[89, 90] Furthermore, in vivo Map infection is associated 
with expression of IL-1β.[91]  It has been suggested that IL-1β plays an important role in the 
pathogenesis of IBD as evidenced by enhanced secretion of Il-1β by mononuclear cells 
isolated from the inflamed mucosa from patients with Crohn’s disease and increased IL-1β 
secretion by murine macrophages which contain the most common susceptibility allele for 
Crohn’s disease which is in the Nod2 locus.[92, 93] Moreover, there is a positive correlation 
between IL-1β levels and the degree of intestinal inflammation in Crohn’s disease. [94]   
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Microbial pathogens have also been linked to reactivation or exacerbation of 
inflammation in IBD patients.[95, 96] However, only a limited numbers of studies have 
examined the role of specific pathogens as causes of enhanced intestinal inflammation and, 
more specifically, even fewer studies have examined the role of occult or subclinical 
infections on the development of intestinal inflammation. In one study it was noted that there 
is an increased prevalence of active cytomegalovirus (CMV) infection in patients with 
IBD.[97] It is speculated that this represents reactivation of latent infection. In support of a 
potential role for CMV, a virus known to infect intestinal macrophages, in reactivation or 
exacerbation of inflammation in IBD,  it has been shown that latent cytomegalovirus 
infection sensitizes mice to a worsening of disease following DSS mediated intestinal 
injury.[98, 99]  These authors established subclinical infection based on the detection of viral 
DNA in various tissues, including the intestines, in the absence of clinical signs of disease 
such as weight loss and gross or occult colonic or rectal blood and the lack of viral induced 
histologic lesions. After the administration of DSS, enhanced disease was demonstrated as 
evidenced by increased weight loss and enhanced gross and histologic lesion scores. These 
authors also reported increased levels of antibodies to commensal bacterial antigens which 
they suggested was due to enhanced gut permeability. They proposed that the exacerbation of 
disease was due to CMV mediated increases in gut permeability that promoted antigen-
specific responses and enhanced the innate immune response following disruption of the 
intestinal mucosa by DSS.     
Additional studies have shown that prior exposure to minimally pathogenic enteric 
microbes, such as Hymenolepis diminuta, Bacteroides fragilis, Candida albicans or AIEC 
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exacerbates subsequent oxazolone or DSS mediated intestinal inflammation.[67, 100, 101] 
With respect to Hymenolepis diminuta, mice were infected and then following a brief 
incubation period were given oxazolone to induce intestinal injury. The combination of H. 
diminuta and oxazolone resulted in both enhanced clinical disease and increased production 
of eosinophil peroxidase (EPO), IL-13, IL-4 and IL-5. The proposed mechanism associated 
with the enhanced disease was an additive Th2 response, with the reasoning being that both 
Hymenolepis diminuta and oxazolone both induce a Th2 polarized immune response, 
suggesting that infection with Hymenolepis diminuta primed the immune response for 
enhanced disease.[100] Interleukin-13 mediated increases in enterocyte apoptosis were 
suggested as one of the specific mechanisms for the observed exacerbation of intestinal 
injury. In contrast, the enhanced disease observed in BALB/c mice infected with an AIEC 
strain of E. coli, a pathogen known to infect macrophages, was associated with increased 
expression of IL-1β and IL-6, with enhanced disease thought to be mediated by AIEC 
flagellin as indicated by increased expression of its receptors, TLR5 and IPAF, and the 
absence of enhanced disease in mutants that lacked flagella.[67]   
Bacterial products such as unmethylated cytosine-guanosine dinucleotides (CpG) 
motifs of bacterial DNA or filamentous hemagglutinin antigen (FHA) can also positively or 
negatively influence the progression of concurrent intestinal inflammation. In the study 
examining the influence of CpG motifs of bacterial DNA, CpG-ODN was inoculated 
intraperitoneally during treatment with DSS which resulted in enhanced intestinal injury as 
demonstrated by increased weight loss, decreased colon lengths and increased histologic 
lesion scores.[102] The mechanism for enhanced disease is not known but these investigators 
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did demonstrate that intraperitoneally inoculated digoxigenin labeled CpG-ODN that CpG-
ODN was delivered to the lamina propria of the intestine and to the mesenteric lymph nodes, 
thereby indicating that CpG-ODN could have a local effect in the intestine following 
intraperitoneal injection.[102] In contrast to the deleterious effect of CpG, subcutaneous 
administration of FHA has been shown to promote the production of IL-10 and TGF-β in 
mesenteric lymph nodes and the Peyer’s patches, the increase of which was associated with 
amelioration of intestinal inflammation experimentally induced by the transfer of CD45RBhi 
cells.[103] In total, these studies suggest that specific microbial pathogens or their products 
can alter intestinal mucosal homeostasis and predispose the host to enhanced intestinal 
injury.   
Non-microbial causes of enhanced intestinal permeability and inflammation: 
Although the normal bacterial flora or, potentially, individual pathogenic species of 
bacteria contribute to the initiation or progression of intestinal inflammation in IBD, it is 
important to note that there are non-microbial or environmental factors that can exacerbate 
pre-existing or subsequent intestinal inflammation. Factors such as oral supplementation of 
iron and psychosocial stress can contribute to the enhancement of chemically induced 
intestinal inflammation. Iron supplementation is often required in chronic inflammatory 
colitis due to anemia and has been associated with exacerbation of disease activity.[104] It is 
speculated that poorly absorbed iron reaches the colon and via the Fenton reaction reacts with 
neutrophil derived free radicals, which can, via lipid peroxidation of cell membranes, 
exacerbate pre-existing intestinal lesions.[105] Addition of iron to the diet of mice being 
administered DSS have worse intestinal inflammation relative to mice given DSS only.[106] 
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The addition of iron was associated with increased IL-1β, myeloperoxidase and inflammatory 
lesion scores, which was ameliorated with anti-oxidant suppplementation.[106] Psychosocial 
stressors also can exacerbate DSS mediated intestinal inflammation. This was demonstrated 
by both overcrowding and imposing social defeat on mice prior to the administration of 
DSS.[107] Social defeat was defined as the repeated placement of mice into a resident male 
mouse’s cage for a prolonged period of time. The mice exposed to the stressors had more 
severe weight loss, increased lesion scores and elevated production of TNF-α, IL-6 and IFNγ 
from cells isolated from the mesenteric lymph nodes.      
Non-steroidal anti-inflammatory drugs (NSAIDs) can also interfere with the normal 
functioning of the intestinal mucosal barrier. Side effects associated with NSAID treatment 
can include reactivation of quiescent IBD or the development of gastrointestinal ulcers and 
perforations.[108-110] These side effects are not only associated with the inhibition of 
cyclooxygenase, but also with damage caused by generation of nitric oxide and oxygen 
radicals.[111-113] Experimentally, aspirin induced increases in gastric epithelial 
permeability are associated with decreased expression of claudin-7, with NSAIDs also being 
shown to alter permeability by interfering with oxidative phosphorylation, that in conjunction 
with suppression of cyclooxygenase, compromises the integrity of the tight junction.[114, 
115] Lastly, alcohol consumption is associated with increased intestinal permeability. 
Acetaldehyde, a byproduct of alcohol consumption, in rats is associated with increased 
intestinal permeability and enhanced endotoxin translocation.[116] This association is 
supported by in vitro studies where exposure of Caco2-cells to acetaldehyde is associated 
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with phosphorylation of E-cadherin and ZO-1 and resulting increased permeability of the 
monolayer.[19]  
The role of macrophages in host homeostasis and inflammation  
Intestinal mucosal macrophages are continual targets for both constituents of the 
normal flora and enteric pathogens, thus it is imperative to understand their homeostatic 
functions and mechanisms that can cause a shift in their phenotype to promote injurious 
inflammation. Therefore, the next section of this review will focus first on the general 
biology of macrophages and then transition to a more focused analysis on the homeostatic 
and potentially pathogenic profiles of intestinal macrophages.  
Macrophage development 
Although resident tissue macrophages have specialized functions that are dependent 
on the organ in which they ultimately reside, they all have a common origin in a bone 
marrow derived progenitor cell which gives rise to the blood monocyte. Blood monocytes 
originate from a progenitor cell that, at least in mice, is capable of differentiating into a 
macrophage or dendritic cell and is CD115+, CD117+, CX3CR1+ and Lin-.[117] In both 
humans and mice, after these macrophage progenitor cells are released into the systemic 
circulation as blood monocytes they have been phenotypically subdivided into “non-
inflammatory” and  “inflammatory” monocytes, primarily based on their expression of 
chemokine receptors.[118] It is this differential chemokine profile which presumably 
influences the selective migration of these two subsets of monocytes. The “non-
inflammatory” monocytes are presumed to develop into resident tissue macrophages and are 
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CCR2-, Gr1-, and CX3CR1+, while the “inflammatory” monocytes of mice are relatively 
short lived and characterized by intermediate expression of CX3R1 and being CCR2+, 
Gr1+.[118]  Therefore, the “inflammatory” monocytes migrate to areas where there is 
increased expression of pro-inflammatory chemokines, such as CXCR2 (IL-8) and MCP-1 
(the CCR2 ligand) while “non-inflammatory” monocytes are chemotactically attracted to 
peripheral tissues that express CX3CR1.[119] After these monocytes home to the peripheral 
tissues and develop into fully differentiated macrophages, their potential to proliferate locally 
is different. For example, Kupffer cells in the liver and alveolar macrophages in the lungs are 
capable of local proliferation in contrast to the non-proliferative potential of intestinal 
macrophages.[120, 121] These studies highlight the dynamic phenotypic properties of 
monocytes which presumably correlate with the final tissue dependent functions of 
macrophages.     
Macrophages as key mediators of inflammation and the innate immune response   
Resident macrophages are strategically located throughout the body in various host 
tissues and organs to optimally perform their roles in host homeostasis and as key effectors in 
the innate and adaptive immune response. It is important to remember that regardless of their 
location, macrophages are phagocytic cells whose physiologic functions are not exclusively 
restricted to host immune defense. Macrophages play a vital role in various homeostatic 
functions such as in the clearance of senescent red blood cells in the red pulp of the spleen 
and in the removal of apoptotic cellular debris in the thymus.[122, 123] These functions are 
mediated by multiple receptors, for example, phosphatidylserine and scavenger receptors, 
and often occur in the absence of obvious inflammation.[124]  Although these functions are 
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often neglected in discussions of macrophages, their role as potent effectors of the host 
immune response is perhaps more important. For example, macrophages kill bacteria. This 
effector function is enhanced in the context of an adaptive immune response, with 
recognition of bacteria being achieved via cell surface associated receptors such as the 
complement receptor 3 (CR3) which results in phagocytosis and formation of the 
phagolysosome.[125] It is within the phagolysosome that lysosomal NADPH oxidases and 
other enzymes promote the generation of antimicrobial substances, such as superoxide anion, 
hydrogen peroxide, and nitric oxide that are directly toxic to bacteria.[125]  
In addition to their antimicrobial effects, macrophages have an equally important role 
as key cellular mediators of inflammation.  In contrast to the non-inflammatory profile of 
macrophages while performing homeostatic functions, macrophages can exert potent pro-
inflammatory effects following infection with bacterial pathogens or exposure to necrotic 
cellular debris derived from various injurious stimuli, for example following physical 
trauma.[126] These pro-inflammatory stimuli are detected by macrophages as a “danger 
signal” and initiates a response that often culminates in inflammation.[126] Some of these 
extracellular “danger signals” include histones, DNA, and heat-shock proteins, which are 
detected by various receptors, for example, intracellular pattern recognition receptors (PRRs) 
and Toll-like receptors (TLRs).[127, 128] Following interaction with receptors, such as 
TLRs, this extracellular signal is often transmitted to the cell nucleus via an adapter protein 
called myeloid differentiation primary response gene 88 (MyD88) which ultimately allows 
for the translocation of an activated transcription factor to the nucleus of the cells, for 
example nuclear factor-κβ (NF- κβ) which promotes the  transcription of pro-inflammatory 
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cytokines such as IL-1β.[129] The production of the pro-inflammatory cytokines IL-1, IL-6 
and TNF-α causes both local and systemic responses in the host. Locally, these factors can 
cause vasodilatation and increased vascular permeability and through the production of IL-8 
can recruit inflammatory cells, such as neutrophils to the site of inflammation.[130] 
Moreover, these molecules act systemically as endogenous pyrogens and induce the 
generation of acute-phase proteins from the liver, including C-reactive protein and mannose 
binding lectin.[130]   
Functional classification of macrophages 
As with the extensive efforts to categorize and define the functional profiles of T-
cells in the adaptive immune response, there have been attempts to develop a classification 
system in which macrophages are subdivided based on their predominant function.  
Previously, macrophages associated with a Th1 or Th2 polarized immune response were 
classified into relatively static categories as classically, M1, or alternatively, M2, 
activated.[131] Classically activated macrophages are the product of a Th1 skewed cell-
mediated immune response characterized by the production of IFNγ, with their primary 
function being to kill intracellular pathogens.[132] On the other hand, macrophages in a Th2 
polarized environment, defined by the presence of IL-4 and IL-13, develop into alternatively 
activated macrophages which often express arginase and mannose receptor (CD206).[133, 
134] However, this system lacks sufficient flexibility to account for the dynamic properties 
of macrophages. A recent report has proposed a new classification system which places 
activated macrophages into a relatively plastic scheme where there is overlap and expansion 
of the number of functions of macrophages.[135] Macrophages within this system are 
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defined as being regulatory, wound-healing, or, as previously used, classically activated 
macrophages. The definition of a classically activated macrophage in this system is similar to 
the original classification scheme and highlights some additional features of this population 
of cells.  
As described previously, classically activated macrophages are effector cells 
generated in the presence of a cell mediated Th1 polarized immune response that require 
IFNγ and TNF-α to be activated.[132, 135] The initial source of the IFNγ can come from 
natural killer cells (NK), with sustained production of IFNγ being derived from antigen-
specific Th1 CD4+ T-cells.[136] Ultimately, the signal from these cytokines are transmitted 
to the nucleus via transcription factors that include signal transducer and activator of 
transcription molecules.[137, 138] An exception to this pathway of activation involves IFNβ, 
which can take the place of IFNγ.[139]  After activation, classically activated macrophages 
acquire enhanced antimicrobial properties, including expression of inducible nitric oxide 
synthase (iNOS), which results in the production of anti-microbial nitrogen radicals, and 
respiratory burst induced increases in the production of antimicrobial oxygen radicals and 
superoxide anion.[140, 141] Although these molecules are effective antimicrobials, they are 
non-specific and can cause extensive collateral tissue damage and contribute to the 
pathogenesis of immune-mediated diseases, such as rheumatoid arthritis.[142] These 
unintended detrimental effects can be further compounded by the generation of Th17 T-cells 
whose formation can be promoted by classically activated macrophages following the 
production of IL-6 and IL-23.[143, 144] The deleterious effects of Th17 cells are mediated 
by the production of IL-17 that induces the recruitment of neutrophils.[145]  
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In addition to responding to an adaptive immune response by developing into potent 
anti-microbial effector cells, macrophages are also capable of modifying the immune 
response in their role as regulatory macrophages. They accomplish this primarily through the 
production of the immunoregulatory cytokines IL-10 and TGF-β and require two signals for 
their generation. These two signals can include IgG immune complexes and a TLR 
agonist.[146] These signals generate a population of regulatory macrophages that produce 
IL-10 and decrease the production of IL-12. Phagocytosis of apoptotic cellular debris is an 
another stimulus that can generate TGF-β producing macrophages which can inhibit the 
production of pro-inflammatory cytokines.[124] In contrast to the subsequently described 
wound-healing macrophages, regulatory macrophages do not promote the production of 
extracellular matrix but do express high levels of the co-stimulatory molecules CD80 and 
CD86, which enables them to present antigens to T-cells.[147] These distinct properties of 
regulatory macrophages emphasize the potentially divergent roles that macrophages can have 
in the immune response, ranging from modulating the overall immune response via IL-10 
production to functioning as a highly effective anti-microbial effector cell.   
   Further highlighting the dynamic functional properties of macrophages is the 
observation that they can function in the response to tissue injury as wound healing 
macrophages. These cells previously were described as alternatively activated macrophages; 
however, since this is not the only other pathway for macrophage activation, it has been 
suggested that this name is misleading. The key cytokines for generating and sustaining this 
subset of macrophages is IL-4 and IL-13, prototypical cytokines of a Th2 type adaptive 
immune response.[147, 148] However, at least experimentally, it has been demonstrated that 
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IL-4 can be produced by mast cells and basophils in an innate immune response following 
injury to tissue.[149]  
  Although anti-helminthic properties have been ascribed to this population of 
macrophages, a primary role of these cells is in the production of extracellular matrix, which 
if overproduced can lead to excessive fibrosis, as demonstrated in experimental 
schistosomiasis infection.[150] Exposure of resident macrophages to IL-4 promotes the 
formation of wound healing macrophages that express the enzyme arginase, which, in turn, 
generates ornithine from arginine. The final product of this response is the formation of 
extracellular matrix via production of polyamines and collagen.[148]  In contrast to the anti-
microbial properties of classically activated macrophages, wound healing macrophages have 
seemingly contradictory abilities in either being able to restrict the growth or be susceptible 
to pathogens such as Mycobacterium tuberculosis and Cryptococcus neoformans. In vitro 
exposure of macrophages to IL-4 or IL-13 results in less production of pro-inflammatory 
cytokines, decreased generation of nitrogen and oxygen free radicals, and impaired killing of 
intracellular pathogens, further implying that the term activated is inappropriate.[147] In 
support of this population of macrophages being more susceptible to certain intracellular 
infections, it has been demonstrated that macrophages treated with IL-4 are more susceptible 
to infection with Mycobacterium tuberculosis because of inhibition of autophagy related 
killing.[151] Additionally, Cryptococcus neoformans grows at a higher rate in mice that 
overproduce IL-13, in contrast to resistance to infection observed in mice that lack IL-
13.[152] With that said, there is evidence that these cells have a role in the clearance of 
helminths, but it is not known if this is due to a direct or indirect inhibitory effect of these 
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macrophages. The anti-helminthic properties are thought to be due to the generation of 
chitinase and chitinase-like molecules, such as stabilin-interacting chitinase-like protein and 
acidic mammalian chitinase.[153, 154]   
 Lastly, the functional ability of a macrophage is not fixed, thus making it difficult to 
define its phenotype.  This can occur because macrophages can co-express markers 
characteristic for different subsets of macrophages. For example, the molecule resistin-like 
molecule-α (RELMα) is expressed by both regulatory and wound-healing type macrophages. 
If macrophages are treated in vitro with IL-4 they have characteristics of wound-healing 
macrophages and express RELMα.[155] After these cells are treated with immune 
complexes, they assume the phenotype of regulatory macrophages whereby they produce IL-
10 and decrease the production of IL-12 yet still express RELMα.[147] Furthermore, in vivo 
it has been suggested that macrophages are capable of shifting their phenotype in different 
diseases. For example, it has been suggested that macrophages through their pro-
inflammatory properties have the potential to contribute to the pathogenesis of neoplasia; but, 
following progression of the neoplastic mass, the characteristics of macrophages can change 
to a regulatory phenotype presumably due to exposure to a tumor associated environmental 
trigger such as hypoxia.[156, 157] [158, 159] In summary, these functional properties of 
macrophages affirm that these cells are not one dimensional anti-microbial effector cells of 
the host immune response but are also capable of modulating the immune response and can 
play a role in the host response to injury.    
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The role of macrophages in intestinal homeostasis: 
Macrophages are dynamic effector cells, whose function  is modulated and defined by 
its local environment  This is equally true for intestinal macrophages which play a critical 
role in maintaining mucosal homeostasis.[160] Therefore it is essential to study the biology 
of intestinal macrophages and understand how local environmental factors such as exposure 
to microbial pathogens or how macrophage specific genetic mutations alters intestinal 
macrophage phenotype and whether these changes translate to increased susceptibility to 
intestinal injury. 
  Intestinal macrophages are strategically situated in the lamina propria of the intestinal 
tract where they can interact with and eliminate bacteria that penetrate the overlying mucosal 
barrier. The morphologic features of the more numerous macrophages in the superficial 
lamina propria are distinct from the macrophages in the deep lamina propria. For example, 
consistent with intestinal macrophage ability to efficiently phagocytose material, 
macrophages in the subepithelial lamina propria have prominent vesicles and abundant 
cytoplasm.[161] Although these differences in morphologic features exist, it is not clear if 
there are differences in phenotype or function of macrophages within different regions of the 
intestine or within different levels of the intestinal wall. Of the total number of mononuclear 
cells in the intestinal tract, approximately 10% are macrophages, with greater numbers in the 
colon.[162, 163]  
Because of the relatively large number of intestinal macrophages and their potential 
to function as potent pro-inflammatory cells it is critical to tightly regulate their behavior to 
prevent unwanted injurious activation.  To accomplish their primary dual function in 
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eliminating bacteria without generating pro-inflammatory cytokines, intestinal macrophages 
have evolved to have both antimicrobial and anti-inflammatory properties. For example, 
although intestinal macrophages have the ability to actively phagocytose and kill bacteria 
they do not function as antigen-presenting cells because of the lack or low expression of 
CD40, CD80 and CD86.[164] [45, 165] Moreover, they are deficient in a wide range of 
receptors that are commonly associated with the production of the pro-inflammatory 
cytokines IL-1β, IL-6, TNF-α, and IL-8; they lack the Fc receptors CD16, CD32, and CD64 
for IgG; CD14, a receptor for LPS, and do not express the Fc receptor for IgA CD89.[45, 
166]   Additionally, they lack multiple complement receptors, such as CR3 (CD11b/CD18) 
and CR4 (CD11c/CD18).[45] The absence of these receptors correlates with an inability of 
intestinal macrophages to produce pro-inflammatory cytokines following stimulation with 
muramyl dipeptides, LPS and heat-killed Staphylococcus aureus or phagocytosis of latex 
bleads.[45, 121] Also, they generally do not express the triggering receptor on myeloid cells-
1 (TREM-1), the activation of which enhances expression of receptors such as CD40 and 
CD86 and the production of pro-inflammatory cytokines.[167-169] The protective properties 
of intestinal macrophages are highlighted in a study where macrophages were either 
systemically or selectively depleted in the intestines. Depletion of intestinal macrophages 
correlated with increased neutrophil infiltration and enhanced DSS mediated intestinal 
inflammation.[170]  In addition to displaying an anti-inflammatory profile, intestinal 
macrophages are capable of modulating the immune response by both inhibiting the 
formation of potentially pathogenic Th17 cells and promoting the formation of regulatory T-
cells.[171]  
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The unique anti-inflammatory profile of intestinal macrophages is supported by both 
the overlying intestinal epithelium and stroma. For instance, in an experimental system 
utilizing intestinal epithelial spheroids, these spheroids promoted the development of 
macrophages which had decreased IL-1β production following stimulation with LPS and had 
decreased expression of the following surface receptors: CD11b, CD11c, CD14 and 
CD16.[172] Although a basement membrane exists between intestinal epithelial cells and 
macrophages in the underlying lamina propria, it is porous enough to allow interaction 
between these two cell types.[173] The intestinal stroma also promotes the development of 
the intestinal macrophage phenotype, with the immunomodulatory cytokines TGF-β and IL-
10 having a primary role in their development.[45, 167, 174] With respect to TGF-β, this is 
based on the observation that incubation of stromal cell culture conditioned medium with 
anti-TGF-β prevented blood monocytes from developing a refractory inflammatory 
profile.[45] The importance of IL-10 in regulating intestinal macrophage function is 
highlighted in mouse models in which IL-10 is absent or IL-10 signaling is disrupted.[175, 
176] For example, in IL-10-/- mice IL-12 and IL-23 secreting macrophages are associated 
with the development of spontaneous colitis.[175] The depletion of these macrophages 
prevents inflammation. Additionally, disruption of macrophage associated IL-10 signaling by 
interfering with Stat3 results in colitis.[176] As exemplified by these IL-10 knockout mouse 
models, despite the protective roles of intestinal macrophages, such as in the clearance of 
bacteria, it is clear that macrophages can contribute to the pathogenesis of intestinal 
inflammation. Moreover, if monocytes are recruited to these sites of inflammation they likely 
do not differentiate into the “normal” intestinal phenotype and may further exacerbate 
35 
 
inflammation due to the presence of luminal bacterial flora or antigens if there is a breach in 
the mucosal barrier.  
Clinical studies in IBD patients have also highlighted the ability of macrophages to 
contribute to the pathogenesis of intestinal inflammation.  It has been documented that, 
unlike normal intestinal macrophages, macrophages in the inflamed intestines of patients 
with IBD express co-stimulatory molecules such as CD80 and CD86 and are almost the 
exclusive source of large amounts of IL-1β.[93, 165, 177] In addition, macrophages in these 
foci of intestinal inflammation have been shown to express TREM-1 and CD14, with 
increased numbers of TREM-1 expressing macrophages in patients with active IBD having a 
corresponding increase in the production of IL-1β and TNFα.[168, 178] The importance of 
TNF-α and macrophages in the pathogenesis of IBD is exemplified by the success of anti-
TNF-α therapy in patients with CD where it is thought that part of the success of this therapy 
is attributed to the elimination of TNF-α  producing macrophages.[179] Although 
macrophages are significant sources of cytokines in IBD, potentially pathogenic effector 
molecules of macrophages are not limited to cytokines. For example, intestinal macrophages 
from patients with IBD have increased expression of tissue degrading cathepsins, with 
amelioration of colitis being described following their inhibition in a chemically induced 
mouse model of colitis.[180]  
Abberant macrophage associated production of IL-1β:     
Intestinal macrophages are a primary source of the pro-inflammatory cytokine IL-1β 
in IBD.[93, 177] The transcription of IL-1β is mediated by NF-κβ and is translated as an 
inactive pre-cursor that requires processing for generation of the mature cytokine.[181, 182] 
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It is the inflammasome, a multi-protein complex, that promotes the processing of IL-1β by 
activating interleukin converting enzyme (ICE) or caspase-1, which, in turn, acts on pro-IL-
1β to form IL-1β.[183] Experimentally, in a study emphasizing the importance of ICE in the 
formation of mature IL-1β, there is a marked reduction in IL-1β with a corresponding 
reduction in DSS mediated intestinal inflammation in ICE knockout mice.[184]  The pro-
inflammatory properties of IL-1β include stimulation of liver produced acute phase proteins, 
increased expression of adhesion molecules on endothelial cells; and, perhaps most 
importantly with respect to IBD, it also can promote enhanced gut permeability through 
increased expression of myosin light chain kinase, resulting in disruption of tight 
junctions.[29, 33, 130]  
Intrinsic defects of intestinal macrophages can compromise intestinal homeostasis 
and aberrantly increase the production of IL-1β. A macrophage associated mutation in the 
nucleotide-binding oligomerization domain 2 (NOD2) protein, which is an intracellular 
pattern recognition receptor stimulated by muramyl dipeptide, have been described in 
patients with CD.[185, 186] An additional macrophage associated defect in CD has revealed 
alterations in autophagy related genes, namely, autophagy-related 16-like 1 (Atg16L1), with 
several authors proposing interactions between the seemingly disparate NOD2, autophagy 
and the inflammasome pathways resulting in a macrophage immunodeficiency and potential 
increases in IL-1β and IL-18 production.[87, 88] Defects and the inter-relatedness of the 
autophagy and NOD2 pathways have recently been described.[187] Normally, NOD2 binds 
muramyl dipeptide and subsequently interacts with the autophagocytic process, which is 
involved in the removal of damaged organelles and defense against intracellular pathogens, 
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by bringing ATG16L1 to the plasma membrane and promotes the formation of the 
autophagolysosome. This ultimately leads to major histocompatibility class II (MHC II) 
being loaded with antigen and clearance of bacteria. Mutations of either NOD2 or ATG16L1 
prevent this process from occurring, with defects in autophagy potentially leading to 
deregulated macrophage inflammasome activity as shown in mice with a mutation in 
ATG16L1 that have increased IL-1β and IL-18 secretion.[87]  
Macrophage associated increases in the production of IL-1β in CD may be associated 
with constitutive activation of the inflammasome, with inflammasome activity being 
indirectly influenced, as mentioned before, by defects in the NOD2 pathway.[188, 189] [88] 
A component of the inflammasome, NACHT-, LRR- and pyrin domain-containing proteins 
(NALP), and NOD2 are members of a relatively new family of PRRs called Nod-like 
receptors (NLRs).[190] Structurally, these PRRs are defined by a C-terminal LRR domain; 
an N-terminal effector domain that can be a caspase recruitment domain (CARD), a pyrin 
domain (PYR) or a baculovirus inhibitor of apoptosis protein repeat (BIR); and an 
intermediary nucleotide binding domain (NOD/NACHT).[191]  The CARDS are involved in 
protein-protein interactions, the nucleotide binding domain mediates self oligomerization 
which is important for the activation of downstream effector molecules, and the LRRs are 
involved in binding bacterial products, in particular muramyl dipeptide (MDP), a structural 
component of bacterial peptidoglycan.[188] Although the inflammasome shares a similar 
subunit with NOD2, it is an independent molecular entity that can be composed of a different 
combination of proteins making up distinct inflammasomes.[192] Assembly of the 
inflammasome is associated with activation of the P2X7 receptor which results in a decrease 
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of intracellular potassium.[193, 194] Originally, the inflammasome was structurally defined 
by apoptosis-associated speck-like protein containing a CARD (ASC), NALP1, caspase-5 
and caspase-1.[195] A more recently described inflammasome brings together two caspase-1 
molecules and is composed of NALP-3 (cryoporin) and two adapter proteins cardinal 
(CARD8) and ASC which associate with the two caspase-1 molecules.[196] It is expressed 
by macrophages and can potentially respond to multiple stimuli, including Staphylococcus 
aureus, adenosine triphosphate (ATP), and uric acid crystals produced from dying cells.[197-
199] Following generation of the mature IL-1β by caspase-1, it needs to be secreted from the 
cell. The mechanisms of its release, relative to its production, are less well defined. It is 
thought that calcium influx concurrent with the activation of multiple phospholipases 
promotes the secretion of mature IL-1β, with another mechanism involving activation of the 
P2X7 receptor with ATP.[200, 201]       
In contrast to the inflammasome, NOD2 is an intracellular sensor of bacteria that can 
contribute to the generation of IL-β via NF-κβ mediated signaling and activation of caspase-1 
or indirectly influence the activity of the inflammasome through interaction with the 
autophagy pathway.[87, 187, 202] NOD2 was the first susceptibility gene associated with 
CD and found to be on chromosome 16q12, with the defect being characterized as a 
frameshift mutation in the leucine rich region of the NOD2 gene that was caused by a 
cytosine insertion, 3020insC.[203, 204] The resulting protein product was predicted to 
encode a truncated protein, with its expression being increased in patients with CD.[203] The 
NOD2 protein detects the GM-Di muropeptide (GlcNAc-MurNAc-L-Ala-D-Glu), which is a 
muramyl dipeptide (MDP) present in almost all bacteria; the exception being bacteria that do 
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not contain peptidoglycan in their cell wall, such as Mycoplasma spp.[205, 206] It is 
expressed by monocytes and its signaling results in the translocation of the transcription 
factor NF- κβ to the nucleus with transcription of, but not limited to, proIL-1β.[202, 207] 
Translocation of NF- κβ to the nucleus is accomplished through the interaction of NOD2 
with a RIP-like interacting CLARP kinase receptor interacting 2 (RICK) protein which is a 
serine/threonine kinase that phosphorylates inhibitor of NF- κβ kinase (IKK).[207, 208]  
It is not entirely apparent if the NOD2 mutation in vivo results in increased or 
decreased function with respect to activation of NF-κβ. Experiments have been conducted in 
mice that contain the most common susceptibility allele of NOD2, the 3020insC.[92] Bone-
marrow derived macrophages from these mice exhibit elevated NF- κβ expression and IL-1β 
secretion following stimulation with MDP and had more severe intestinal inflammation 
following induction of colitis with dextran sodium sulfate. However, other studies have 
suggested that NOD2 disease variants have a loss of function phenotype based on the 
observation of decreased IL-1β following stimulation with muramyl dipeptide or 
peptidoglycan.[209]  
In conclusion, although the aforementioned studies demonstrate that intestinal 
macrophages have important homeostatic or potentially pathogenic properties, additional 
studies are warranted to better define whether or not chronic intestinal infections of 
macrophages can cause a shift in macrophage effector function that disrupts the mucosal 
barrier or impairs the host response to mucosal injury.  
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Abstract 
Intestinal macrophages are dynamic effector cells which play a critical role in maintaining 
mucosal homeostasis. Superimposed acute exposure to low-level microbial pathogens, such 
as adherent/invasive strain of E. coli (AIEC), that survive within intestinal macrophages can 
exacerbate experimental intestinal inflammation. However, it is not known how occult 
intestinal infections alter the response of the intestinal mucosa to subsequent intestinal injury. 
The aim of this study was to evaluate how persistent subclinical intestinal infection with 
Mycobacterium avium subsp. paratuberculosis (Map) would influence subsequent acute 
dextran sulfate sodium (DSS) mediated intestinal inflammation. BALB/c mice were infected 
intraperitoneally with Map. Following an incubation period of 90 days, mice were 
administered 2% DSS in the drinking water for 6 days. Prior to and during treatment with 
DSS mice were evaluated for clinical signs of disease and body weights were recorded. At 
the termination of the experiment, body weights, frequency of rectal blood, gross and 
histologic cecal lesions were evaluated and tissues were collected for isolation of Map. 
Subclinical and persistent intestinal Map infection was established based on the absence of 
both weight loss and rectal blood. Following treatment with DSS, Map infected mice had 
increased weight loss, increased frequency of rectal blood, and exacerbation of gross lesions 
and increased cecal lesion scores. Also, there was a significant reduction in Map isolated 
from the small intestines of Map infected and DSS treated mice. In conclusion, subclinical 
Map infection sensitizes the host to enhanced acute DSS mediated intestinal inflammation.  
Key words: Dextran sulfate sodium, Mycobacterium avium subsp. paratuberculosis, 
subclinical infection, enhanced inflammation   
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Introduction 
Intestinal mucosal macrophages are continual targets for enteric pathogens, thus it is 
imperative to understand mechanisms that balance macrophage effector function with 
mucosal homeostasis. For example, in Crohn’s disease (CD), a chronic inflammatory disease 
of the gastrointestinal tract, a disorder of macrophage function resulting in impaired bacterial 
clearance and cytokine secretion has been described, with some investigators suggesting that 
CD represents a primary immunodeficiency of macrophages.[1, 2] What is less clear is what 
role, if any, intestinal pathogens that target macrophages have in CD and, more specifically, 
what impact subclinical intestinal infections have on the homeostasis of the intestinal 
mucosa.  
The most convincing support for the role of a specific intestinal pathogen in IBD has 
been demonstrated in patients with ileal CD, where an increased number of patients are 
colonized by an adherent/invasive strain of E. coli (AIEC).[3] It has been reported that AIEC 
was recovered from 36% of mucosal biopsy specimens from patients with early postresection 
recurrent CD relative to 6% of normal control ileal biopsy specimens.[4, 5] This strain of E. 
coli is able to both replicate and persist within macrophages and enhance macrophage 
secretion of TNF. [6]  
There has also been an association between exposure to Mycobacterium avium ss 
paratuberculosis (Map) and CD.[7] Map has been detected by in situ hybridization, PCR and 
bacterial isolation in patients with CD.[8-10] However, contradictory reports exist on the 
significance of Map in the pathogenesis of CD. For example, some studies have not detected 
Map 16s rRNA in patients with CD or UC; and, even though a subset of CD patients may 
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have genetic defects that affect innate immune function; namely, the NOD2 mutation, which 
may predispose patients to an intracellular pathogen such as Map, there is a lack of an 
association between NOD2 polymorphisms and Map infection.[11-13]   
Limited studies have examined the role of occult infections on the development of 
intestinal inflammation. It has been noted that there is an increased prevalence of active 
cytomegalovirus (CMV) infections in patients with IBD.[14] It is speculated that this 
represents reactivation of a latent infection. In support of a potential role for CMV in IBD it 
has been shown that mice with pre-existing subclinical CMV infection have enhanced 
disease following dextran sulfate sodium (DSS) mediated colitis.[15] Additional studies have 
demonstrated that prior exposure to opportunistic pathogens, such as Hymenolepis diminuta , 
Bacteroides fragilis or an adherent/invasive strain of E. coli exacerbates subsequent 
oxazolone or DSS mediated intestinal inflammation.[16-18] In addition to specific 
pathogens, several studies have indicated that extra-intestinal exposure to bacterial products, 
such as unmethylated cytosine-guanosine dinucleotides (CpG) or staphylococcal enterotoxin 
B, may also influence intestinal inflammation.[19, 20] Collectively, these studies suggest that 
specific microbial pathogens or their products can alter intestinal mucosal homeostasis and 
predispose the host to enhanced intestinal injury.  
Considering the ongoing potential for intestinal exposure to pathogenic and 
environmental species of mycobacteria, we set out to understand how exposure to Map 
would impact mucosal homeostasis. Our hypothesis was that exposure to Map would 
enhance acute mucosal injury. To address this goal, we utilized a mouse model of intestinal 
Map infection.[21, 22] BALB/c mice were infected with Map for 90 days followed by 
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exposure to a low dose of DSS in the drinking water to induce mild intestinal injury. In these 
mice we evaluated clinical signs of disease and development of mucosal pathology before 
and after intestinal injury. Our results demonstrate that subclinical intestinal mycobacterial 
infection amplifies the severity of DSS mediated intestinal inflammation as demonstrated by 
enhanced clinical disease, exacerbation of gross lesions and increased lesion scores.   
Materials and Methods 
Animals.  
Conventionally reared 6-8 week-old male BALB/c mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME) weighing approximately 22-24 grams and were 
housed in isolation at the Iowa State University College of Veterinary Medicine biosafety 
level II animal care facility. All animal experiments were approved by the Institutional 
Animal Care and Use Committee of Iowa State University.  
Bacterial inoculum and infection. 
 The Map strain K10 was a clinical isolate obtained from the National Animal 
Disease Center (Ames, IA) and maintained in Middlebrook 7H9 broth supplemented with 
mycobactin J. Logarithmic growth-phase bacteria were washed and resuspended in sterile 
saline for inoculation. Bacterial concentration was determined by measuring absorbance at 
540 nm, comparing the absorbance optical density to the standard curve and adjusted to a 
final concentration of 1x108 colony-forming units. Controls were given a sham inoculation of 
saline. The Map inoculum used in these studies was shown to have greater than 90% viability 
via fluorescein diacetate staining and flow cytometric analysis prior to inoculation. In 
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addition, challenge inocula were confirmed negative for contaminants by streaking onto 
sheep blood agar plates 24 h prior to inoculation.  
Experimental design.   
In three separate experiments, 10-11 mice per treatment group were given a single 
intraperitoneal injection of Map or sham inoculated with saline. Following inoculation, body 
weights of the mice were measured at weekly intervals and feces were periodically collected 
for isolation of Map. At approximately 3 months post-inoculation, acute intestinal injury was 
chemically induced by administering a suboptimal (as discussed below) concentration of 2% 
DSS (MP Biomedicals, Solon, OH ) in the drinking water for 6 days. We established this 
dose by determining the lowest DSS concentration in the drinking water that would induce 
minimal but perceptible microscopic lesions in the cecal and colonic mucosa of DSS only 
treated mice. Using a pilot study we tested doses that ranged from 1-5% DSS, increasing by 
0.5% DSS in each treatment group. 2% DSS induced consistent mild multifocal villus 
elongation with minimal erosions of the mucosal epithelium. This dose was selected for all 
experiments in this study.  While the mice were administered DSS, they were weighed daily, 
evaluated for clinical signs of disease, such as the presence of rectal blood and huddling, on 
day 6 all of the mice were euthanized with CO2 and necropsies were preformed. At necropsy, 
body weight and colon and cecal length were measured. Additionally, sections of spleen, 
liver, small and large intestine were collected for histopathology and isolation of Map. 
Additionally, saline washes from the abdominal cavity were collected and inoculated onto 
7H10 agar for isolation of Map.   
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Histopathology.  
At necropsy, samples of liver, spleen, small intestine, mesenteric lymph node, cecum, 
and colon were fixed in 10% neutral buffered formalin, processed by routine methods, 
embedded within paraffin wax and sectioned. Sections of tissue (5 µm) were stained with 
hematoxylin and eosin. Cecal histologic lesion scores were generated based on the severity of 
mucosal epithelial erosion and hyperplasia, the degree of lamina propria inflammatory cell 
infiltrate, and edema (Table 1).   
Acid-fast staining (Ziehl-Neelsen method).  
Slides were deparaffinized and rehydrated in distilled water. Carbol fuchsin solution 
was added for 45 seconds while microwaving at 450 W. Slides were rinsed in 0.5% acid 
alcohol for decolorization, rinsed for 1 minute in tap water then counterstained in methylene 
blue for 1 minute. 
Culture of M. avium ss paratuberculosis from tissues and feces.  
Sections of spleen, liver, small intestine, and colon were collected for isolation of 
Map.  Each piece of tissue was weighed and homogenized in 0.75% hexadecylpyridinium 
chloride solution and allowed to stand overnight at room temperature to decontaminate the 
cultures. Sediments from individual tissue homogenates (100 μl) were inoculated onto 
Middlebrook 7H10 agar.  Additionally, the peritoneum was washed with saline and 100 μl 
was plated onto Middlebrook 7H10 agar. After 12 weeks of incubation at 37°C, the number 
of colonies was counted. Fecal pellets were collected from each group of mice at 
approximately 14 day intervals until the end of the experiment. The fecal pellets were 
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homogenized in 1 ml of 0.05% Tween 80, diluted, decontaminated and plated on 
supplemented 7H10 agar as described above.  
Statistical analysis.  
Changes in body weight were analyzed using an ANOVA model with repeated 
measures. Map infection or saline inoculation, DSS or water administration, day and their 
interactions were considered as fixed effects, with animal being the subject of repeated 
measures.  On each day, the treatment group means were compared first with an overall F-
test and then followed by post-hoc Tukey-Kramer’s t-test for multiple comparisons if the F-
test was significant. A p-value of < 0.05 was considered significant. For all other parameters, 
treatment group means were compared first with an overall F-test and then followed by post-
hoc Student’s t-test with group mean differences considered significant if the p-value was < 
0.05. Data are presented as the mean value ± standard error of the mean except where stated 
otherwise.  
Results 
Clinical disease and gross lesions  
 In order to establish Map infection we inoculated BALB/c mice with 108 CFU of Map 
strain K10 by a single intraperitoneal injection. Mice infected with Map transiently lost up to 
1 gram of their body weight within the first 7 days after inoculation relative to mice given a 
sham inoculation with saline (data not shown). However, mice recovered their body weights 
and by the end of the 90 day incubation period all treatment groups had similar body weights. 
Other than transient weight loss, inoculation with Map did not cause signs of clinical disease.   
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To evaluate clinical disease we monitored body weight and rectal bleeding. 
Significant weight loss was only identified in the Map + DSS mice and occurred on day 6 of 
DSS administration (Fig. 1, p < 0.03). Rectal bleeding (Table 2) occurred only in treatment 
groups given DSS and coincided with onset of weight loss. There was a greater frequency of 
rectal blood in Map + DSS mice; 40% of Map + DSS mice had rectal blood compared to 
14% of DSS only mice.  
A consistent feature in the murine DSS colitis model is cecal and colonic shortening 
(atrophy) and this was used as a measure of gross pathology in this model (Fig. 2).[23] Cecal 
atrophy was most severe in the Map + DSS group (Fig. 3, **, p < 0.0001). DSS only had 
significant cecal shortening relative to the negative control and the Map K10 only group (Fig. 
3*, p <0.03). Map only mice had cecal lengths similar to the negative control.  We observed 
similar trends in the colon for gross and histologic lesions, with significant shortening of the 
colon in Map + DSS mice compared to all other treatment groups; however, we chose to 
focus our analysis on the cecum because it had more severe and consistent lesions.   
Cecal histologic lesion scores 
Microscopic lesions were typical of the DSS mucosal injury model and were defined 
by a multifocal proliferative to ulcerative typhlitis and colitis (Fig. 4). In the DSS only group 
there was mild multifocal gland proliferation and rare mucosal ulceration. The histologic 
score was not significantly different between the DSS only and the negative control and Map 
only groups. In contrast, the lesions were more severe and widespread in the Map + DSS 
group. (Fig. 5, *, p < 0.0013).  Inoculation with Map alone did not induce histologic lesions. 
Lesions within the large intestine have been reported for BALB/c mice infected with Map 
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19698; however, lesions were not prominent until 32 weeks after infection and did not 
specify whether they were located in the cecum.[24]   
M. avium subsp. paratuberculosis tissue colonization 
The distribution of Map in tissues was similar to that reported previously for Map 
infected BALB/c mice.[22] Map was isolated from spleen, liver, peritoneum, small intestine 
and large intestine, with the greatest concentration of bacteria being isolated from the spleen 
(Fig. 6). Map was not isolated from uninfected control mice. DSS administration had a 
significant effect on Map load only in the small intestine where DSS administration 
corresponded to lower CFU in Map infected mice (Fig. 6,*, p = 0.043). There was a trend for 
decreased numbers of Map CFU in the colon of mice given DSS, but this did not reach 
statistical significance. Map was not isolated from the feces from any of the treatment 
groups.  
Acid-fast stains of tissues  
 Acid-fast bacilli were present within foci of granulomatous inflammation in the liver, 
spleen, peritoneum, cecum, and small intestine. Consistent with the isolation results there 
was a greater density of acid-fast bacilli in the spleen, liver, and at the site of inoculation in 
the peritoneum compared to the small and large intestine.  In the small and large intestine 
low numbers of acid fast bacilli were identified within the mucosa. In the large intestine acid 
fast bacilli were most commonly associated with gut associated lymphoid tissue. Acid-fast 
bacilli were present in cells with macrophage morphology.  
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Discussion 
We set out to explore how occult intestinal infection would influence intestinal 
homeostasis, specifically enteric mycobacterial infection. This is relevant considering the 
frequency of enteric mycobacterial infection in HIV patients, and the potential for 
opportunistic infections in individuals with persistent intestinal inflammation, such as those 
with IBD. [25] In this study we have demonstrated that in our model subclinical Map 
infection sensitizes mice to enhanced DSS mediated intestinal injury. Mice infected with 
Map and treated with DSS had increased weight loss and frequency of rectal blood, increased 
cecal lesion scores and more severe cecal atrophy. These observations suggest that 
mycobacterial infection alters the mucosal response to injury and potentially influences 
repair mechanisms.   
Map infection alone resulted in persistent infection but did not induce clinical disease 
as indicated by the absence of weight loss and lack of rectal blood. Infection was successfully 
established as demonstrated by the isolation of Map from the spleen, liver, small and large 
intestines, and peritoneum; the demonstration of acid-fast bacilli from tissues in which 
bacteria were isolated, which in the small and large intestines were often present in the gut 
associated lymphoid tissue (GALT); and the presence of foci of granulomatous inflammation 
in the spleen, liver and peritoneum. Even though bacteria were isolated and acid-fast bacilli 
were demonstrated in both the small and large intestines, areas of granulomatous 
inflammation were not present in these tissues. The bacterial numbers recovered from the 
small and large intestine were low, which is consistent with prior studies in the  BALB/c 
mouse.[26] This condition bears similarities to occult abdominal Mycobacterium avium 
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infection in humans where disease is absent and bacterial burdens are low.[25] Collectively, 
we believe these findings support the use of this model to better understand how occult 
intestinal infections alter the mucosal response to subsequent intestinal injury.   
When enteric pathogens are recognized the mucosal immune response must control 
pathogen proliferation and dissemination, yet minimize inflammation and injury.  It has 
become clear that intestinal macrophages play a critical role in maintaining the balance 
between mucosal defense and homeostasis.[27]  With respect to their homeostatic role, 
resident intestinal macrophages have a unique functional phenotype. They can eliminate 
potential pathogens while at the same time preventing excessive inflammation.[28] This anti-
inflammatory phenotype of human intestinal macrophages is defined by the absence of innate 
response receptors such as receptors for LPS (CD14) and CR4 (CD11c/CD18) and the 
inability to produce pro-inflammatory cytokines in response to inflammatory stimuli.[28] 
Despite this dual protective role of intestinal macrophages, it is clear that macrophages can 
contribute to the pathogenesis of mucosal injury, such as in IBD where it has been 
documented that large amounts of IL-1β are produced almost exclusively by intestinal 
macrophages.[29, 30] Although these studies demonstrate that intestinal macrophages have 
important homeostatic or potentially pathogenic roles in the intestinal mucosa, it is unclear 
whether or not pathogens that target macrophages can cause a shift in macrophage effector 
function that impairs the host response to mucosal injury. In this study we have demonstrated 
that an occult infection with a pathogen targeting intestinal macrophages is capable of 
augmenting subsequent intestinal injury. In future studies it is our aim to try and determine if 
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Map infected macrophages have an enhanced pro-inflammatory profile following injury to 
the intestinal mucosa.    
Regardless of the trigger utilized to initiate intestinal inflammation, superimposed 
acute exposure to low-level microbial pathogens, some of which target intestinal 
macrophages, can exacerbate intestinal inflammation. To the authors’ knowledge, only one 
other study, similar to the current one, has been described in which latent cytomegalovirus 
infection, a virus known to infect intestinal macrophages,[31] sensitized mice to a worsening 
of disease following treatment with DSS.[15]  Although infection was established in these 
mice based on the detection of viral DNA in various tissues, including the intestines, clinical 
signs of disease such as weight loss and gross or occult colonic or rectal blood were not 
observed, in addition to the absence of viral induced histologic lesions. After the 
administration of a similar dose of DSS used in the current study, enhanced disease was 
demonstrated in those mice subclinically infected with CMV, as evidenced by increased 
weight loss and enhanced gross and histologic lesion scores. One other study has evaluated 
the affect of Map in a model of intestinal injury. Increased weight loss and increased colonic 
lesion scores following oral challenge with live Map, strain Ben (ATCC 43544), has been 
demonstrated in an IL-10 deficient mouse model of spontaneous colitis.[32] In this same 
study there was enhanced production of Ag85B/MPT59 peptide 25 specific TNF-α and IFNγ 
from both serum and cells isolated from the Peyer’s patches and mesenteric lymph nodes. 
The author’s proposed that since Ag85B/MPT59 peptide 25 is conserved across several 
mycobacterial species, that Map may function as an immunomodulator that stimulates T-cells 
in a manner similar to a superantigen, suggesting that the enhanced disease observed in these 
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mice is not unique to Map. Unlike the current study, colonization of the intestine with Map 
was not demonstrated. The absence of IL-10, a key immune regulatory cytokine, [33] is a 
confounding factor which is not present in our model where immunocompetent BALB/c 
mice were used. Additionally, augmented chemically mediated intestinal inflammation has 
been shown following acute luminal exposure to Bacteroides fragilis, AIEC, and 
Hymenolepis diminuta.[16-18] However, unlike the current study where we have 
demonstrated enhanced disease in mice with chronic intestinal mycobacterial infection; these 
models are not able to address how subclinical infection affects the mucosal response to 
injury.   
Even though oral exposure to Map is presumably the natural route of infection in 
cattle,[34] we chose to inoculate mice intraperitoneally in order to establish more consistent 
colonization of the intestine. Previous studies in mice have achieved intestinal colonization 
after 6 or 18 weeks following intraperitoneal inoculation in immunocompetent BALB/c 
mice.[22, 24] In contrast, following inoculation by the intragastric route in flora defined 
mice, colonization of the cecum by Map could not be demonstrated after the first week post-
inoculation.[26] Only if germ-free mice were orally inoculated could consistent intestinal 
colonization be established in immunocompetent mice.[26] In our study intestinal 
colonization was demonstrated by isolation of bacteria from both the small and large 
intestines and by demonstration of acid-fast bacilli that were often present in gut-associated 
lymphoid tissue (GALT).  In addition to the intestines, and, consistent with previous studies 
in BALB/c mice, the greatest concentration of bacteria was isolated from the liver and spleen 
and was not significantly affected by treatment with DSS.[24] However, a smaller number of 
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bacteria were isolated from the small intestines with a trend, but not statistically significant, 
for smaller numbers to be isolated from the large intestine in those mice treated with DSS. 
This result was not anticipated and may partially be explained by an enhanced non-specific 
immune response induced by DSS. Dextran sulfate has been demonstrated in colonic 
macrophages in a DSS mediated mouse model of colitis.[35] Moreover, it has been shown 
that DSS-pulsed macrophages promote the proliferation of T-cells from colitic mice.[36] 
However, we did not observe, by routine histologic stains, a relative increase in the number 
of lymphocytes in the lamina propria of the small intestine or hyperplasia of the GALT. 
Additional studies need to be conducted to precisely define the influence of DSS on the 
replication of Map.    
Most studies utilizing the DSS model of intestinal injury evaluate its effect on the 
colon.[15, 35] Although the colon was significantly affected in our model, we chose to focus 
on the cecum because initial experiments demonstrated more severe gross and histologic 
lesions in the cecum and were able to demonstrate consistent colonization of the cecum by 
both bacterial isolation and demonstration of acid-fast bacilli in the cecal lymphoid tissue. 
Involvement of the cecum is not uncommon following treatment with DSS and, the cecum 
itself, appears to play a central role in the development of experimental colitis. In particular, 
the GALT in the distal tip of the cecum, or sometimes referred to as the appendix of the 
mouse, may be an important factor in the development of colitis. Following experimental 
removal of the murine appendix, clinical disease and lesions associated with DSS 
administration are improved.[37] In support of this observation, it has been noted in humans 
that removal of the appendix reduces the risk of developing ulcerative colitis.[38] The 
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mechanism associated with this protective effect is not known, but functional differences 
between lymphoid tissue of the Peyer’s patches and appendix have been demonstrated, and it 
has been suggested that the appendix is the major priming site for cells involved in the 
development of experimental colitis in the TCRα deficient mouse model of inflammatory 
bowel disease.[39]     
  We believe our model can be utilized to better understand how persistent infection 
with a low-level microbial pathogen, such as Map, disrupts the regulation of intestinal 
homeostasis and tips the balance in favor of enhanced inflammation following injury to the 
intestine. Enhanced disease in our model may be associated with Map mediated exacerbation 
of inflammation, disruption of repair mechanisms, or a combination of both. Future studies 
with this model will define the immune profile of the locally injured intestinal mucosa and 
attempt to characterize how chronic mycobacterial infection modifies the function and 
phenotype of intestinal macrophages, which are critical components of an elaborate 
regulatory system that maintains the intestine in a non-inflammatory state despite the 
presence of large numbers of bacteria in the adjacent intestinal lumen.  
Acknowledgements 
We thank Elise Huffman for technical assistance. This work was funded through a 
Iowa State University research grant and the Iowa Healthy Livestock Initiative. 
 
 
 
 
76 
 
References: 
 
1. Casanova JL, Abel L: Revisiting Crohn's disease as a primary immunodeficiency 
of macrophages. J Exp Med 2009, 206(9):1839-1843. 
2. Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJ, Sewell GW, Palmer CD, 
Wilde J, Foxwell BM, Gloger IS et al: Disordered macrophage cytokine secretion 
underlies impaired acute inflammation and bacterial clearance in Crohn's 
disease. J Exp Med 2009, 206(9):1883-1897. 
3. Barnich N, Darfeuille-Michaud A: Adherent-invasive Escherichia coli and Crohn's 
disease. Curr Opin Gastroenterol 2007, 23(1):16-20. 
4. Neut C, Bulois P, Desreumaux P, Membre JM, Lederman E, Gambiez L, Cortot A, 
Quandalle P, van Kruiningen H, Colombel JF: Changes in the bacterial flora of the 
neoterminal ileum after ileocolonic resection for Crohn's disease. Am J 
Gastroenterol 2002, 97(4):939-946. 
5. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer 
MA, Swidsinski A, Beaugerie L, Colombel JF: High prevalence of adherent-
invasive Escherichia coli associated with ileal mucosa in Crohn's disease. 
Gastroenterology 2004, 127(2):412-421. 
6. Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud 
A: Adherent invasive Escherichia coli strains from patients with Crohn's disease 
survive and replicate within macrophages without inducing host cell death. Infect 
Immun 2001, 69(9):5529-5537. 
7. Chiodini RJ, Van Kruiningen HJ, Thayer WR, Merkal RS, Coutu JA: Possible role of 
mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium 
species isolated from patients with Crohn's disease. Dig Dis Sci 1984, 
29(12):1073-1079. 
8. Sechi LA, Mura M, Tanda F, Lissia A, Solinas A, Fadda G, Zanetti S: Identification 
of Mycobacterium avium subsp. paratuberculosis in biopsy specimens from 
patients with Crohn's disease identified by in situ hybridization. J Clin Microbiol 
2001, 39(12):4514-4517. 
9. Sechi LA, Scanu AM, Molicotti P, Cannas S, Mura M, Dettori G, Fadda G, Zanetti S: 
Detection and Isolation of Mycobacterium avium subspecies paratuberculosis 
from intestinal mucosal biopsies of patients with and without Crohn's disease in 
Sardinia. Am J Gastroenterol 2005, 100(7):1529-1536. 
10. Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G, 
Pickup R, Hermon-Taylor J: Detection and verification of Mycobacterium avium 
subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from 
77 
 
individuals with and without Crohn's disease. J Clin Microbiol 2003, 41(7):2915-
2923. 
11. Bernstein CN, Wang MH, Sargent M, Brant SR, Collins MT: Testing the interaction 
between NOD-2 status and serological response to Mycobacterium 
paratuberculosis in cases of inflammatory bowel disease. J Clin Microbiol 2007, 
45(3):968-971. 
12. Sechi LA, Gazouli M, Ikonomopoulos J, Lukas JC, Scanu AM, Ahmed N, Fadda G, 
Zanetti S: Mycobacterium avium subsp. paratuberculosis, genetic susceptibility 
to Crohn's disease, and Sardinians: the way ahead. J Clin Microbiol 2005, 
43(10):5275-5277. 
13. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR: 
Molecular-phylogenetic characterization of microbial community imbalances in 
human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007, 
104(34):13780-13785. 
14. Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A: Frequent 
detection of cytomegalovirus in the intestine of patients with inflammatory bowel 
disease. Inflamm Bowel Dis 2006, 12(9):879-884. 
15. Onyeagocha C, Hossain MS, Kumar A, Jones RM, Roback J, Gewirtz AT: Latent 
cytomegalovirus infection exacerbates experimental colitis. Am J Pathol 2009, 
175(5):2034-2042. 
16. Hunter MM, Wang A, McKay DM: Helminth infection enhances disease in a 
murine TH2 model of colitis. Gastroenterology 2007, 132(4):1320-1330. 
17. Rabizadeh S, Rhee KJ, Wu S, Huso D, Gan CM, Golub JE, Wu X, Zhang M, Sears 
CL: Enterotoxigenic bacteroides fragilis: a potential instigator of colitis. Inflamm 
Bowel Dis 2007, 13(12):1475-1483. 
18. Carvalho FA, Barnich N, Sauvanet P, Darcha C, Gelot A, Darfeuille-Michaud A: 
Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured 
mouse colon via signaling by flagellin. Inflamm Bowel Dis 2008, 14(8):1051-1060. 
19. Yang PC, Liu T, Wang BQ, Zhang TY, An ZY, Zheng PY, Tian DF: Rhinosinusitis 
derived Staphylococcal enterotoxin B possibly associates with pathogenesis of 
ulcerative colitis. BMC Gastroenterol 2005, 5:28. 
20. Obermeier F, Dunger N, Deml L, Herfarth H, Scholmerich J, Falk W: CpG motifs of 
bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J 
Immunol 2002, 32(7):2084-2092. 
21. Chiodini RJ, Buergelt CD: Susceptibility of Balb/c, C57/B6 and C57/B10 mice to 
infection with Mycobacterium paratuberculosis. J Comp Pathol 1993, 109(4):309-
319. 
78 
 
22. Tanaka S, Sato M, Taniguchi T, Yokomizo Y: Histopathological and 
morphometrical comparison of granulomatous lesions in BALB/c and C3H/HeJ 
mice inoculated with Mycobacterium paratuberculosis. J Comp Pathol 1994, 
110(4):381-388. 
23. Mahler M, Bristol IJ, Leiter EH, Workman AE, Birkenmeier EH, Elson CO, 
Sundberg JP: Differential susceptibility of inbred mouse strains to dextran sulfate 
sodium-induced colitis. Am J Physiol 1998, 274(3 Pt 1):G544-551. 
24. Tanaka S, Itohara S, Sato M, Taniguchi T, Yokomizo Y: Reduced formation of 
granulomata in gamma(delta) T cell knockout BALB/c mice inoculated with 
Mycobacterium avium subsp. paratuberculosis. Vet Pathol 2000, 37(5):415-421. 
25. Greenson JK, Belitsos PC, Yardley JH, Bartlett JG: AIDS enteropathy: occult 
enteric infections and duodenal mucosal alterations in chronic diarrhea. Ann 
Intern Med 1991, 114(5):366-372. 
26. Hamilton HL, Follett DM, Siegfried LM, Czuprynski CJ: Intestinal multiplication 
of Mycobacterium paratuberculosis in athymic nude gnotobiotic mice. Infect 
Immun 1989, 57(1):225-230. 
27. Weber B, Saurer L, Mueller C: Intestinal macrophages: differentiation and 
involvement in intestinal immunopathologies. Semin Immunopathol 2009, 
31(2):171-184. 
28. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin 
WH, Orenstein JM, Smith PD: Human intestinal macrophages display profound 
inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin 
Invest 2005, 115(1):66-75. 
29. Mahida YR, Wu K, Jewell DP: Enhanced production of interleukin 1-beta by 
mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's 
disease. Gut 1989, 30(6):835-838. 
30. Cappello M, Keshav S, Prince C, Jewell DP, Gordon S: Detection of mRNAs for 
macrophage products in inflammatory bowel disease by in situ hybridisation. 
Gut 1992, 33(9):1214-1219. 
31. Redman TK, Britt WJ, Wilcox CM, Graham MF, Smith PD: Human 
cytomegalovirus enhances chemokine production by lipopolysaccharide-
stimulated lamina propria macrophages. J Infect Dis 2002, 185(5):584-590. 
32. Singh UP, Singh S, Singh R, Karls RK, Quinn FD, Potter ME, Lillard JW, Jr.: 
Influence of Mycobacterium avium subsp. paratuberculosis on colitis 
development and specific immune responses during disease. Infect Immun 2007, 
75(8):3722-3728. 
79 
 
33. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient 
mice develop chronic enterocolitis. Cell 1993, 75(2):263-274. 
34. Kreeger JM: Ruminant paratuberculosis--a century of progress and frustration. J 
Vet Diagn Invest 1991, 3(4):373-382. 
35. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R: A novel 
method in the induction of reliable experimental acute and chronic ulcerative 
colitis in mice. Gastroenterology 1990, 98(3):694-702. 
36. Shintani N, Nakajima T, Sugiura M, Murakami K, Nakamura N, Kagitani Y, Mayumi 
T: Proliferative effect of dextran sulfate sodium (DSS)-pulsed macrophages on T 
cells from mice with DSS-induced colitis and inhibition of effect by IgG. Scand J 
Immunol 1997, 46(6):581-586. 
37. Krieglstein CF, Cerwinka WH, Laroux FS, Grisham MB, Schurmann G, Bruwer M, 
Granger DN: Role of appendix and spleen in experimental colitis. J Surg Res 2001, 
101(2):166-175. 
38. Koutroubakis IE, Vlachonikolis IG: Appendectomy and the development of 
ulcerative colitis: results of a metaanalysis of published case-control studies. Am 
J Gastroenterol 2000, 95(1):171-176. 
39. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK: Role of appendix in the 
development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp 
Med 1996, 184(2):707-715. 
 
 
 
 
 
 
 
 
 
80 
 
Table 1  
Cecal lesion scoring system 
 
Parameters      Scoring Criteria 
Enterocyte hyperplasia    Ratio of crypt depth to width 
Rising score from 0 to 3 (no hyperplasia  severe hyperplasia) 
Inflammatory score                     Denotes cellular infiltrates in the lamina propria or cellular 
exudates overlying areas of mucosal ulceration 
Rising score from 0 to 3 (small  large numbers of inflammatory 
cells)  
Mucosal erosions  Rising score from 0 to 3 (no erosions  ulceration) 
Edema     Rising score from 0 to 3 (no edema  marked submucosal edema) 
Distribution   Rising score from 0 to 3 
  (0 = lesion is not present; 1 = < 25%; 2 = 25 – 75%; and 3 = > 75% of the section is affected) 
 
Parameters are scored (0  3) + distribution (0  3) resulting in a maximal total histological score of 
24. 
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Table 2. 
                 
                 Treatment                         Severity of Rectal Blood             % with Rectal Blood 
 
Map only 
-                                                  0% 
 
DSS only 
                  +                                                   14% 
 
Map + DSS 
               ++/+++                                            40% 
 
Severity and % of mice with rectal blood that were either infected with Map or inoculated 
with saline after the administration of DSS or water. A greater percentage of Map + DSS 
mice had rectal blood compared to all other treatment groups.  Data are represented as the % 
of affected mice from three separate experiments including 22 DSS only mice, 25 Map + 
DSS mice, 8 Map only mice.  
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Fig. 1.  Change in body weight in mice inoculated with saline (Control); infected with Map 
only (Map only); inoculated with saline and treated with DSS (DSS only); and mice infected 
with Map and treated with DSS (Map + DSS). Map + DSS mice lost a statistically significant 
amount of body weight relative to all other treatment groups (*, p < 0.03).  Data are 
represented as the mean ± standard error of the means from three separate experiments 
including 22 DSS only mice, 25 Map + DSS mice, 8 Map only and 9 control mice.  
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Figure. 2. Representative pictures demonstrating cecal atrophy. Map only (A); DSS only 
(B); and Map + DSS (C).  Note that there is also shortening of the colon and a reduction in 
the number of formed fecal pellets in the mice administered DSS.  
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Fig. 3. Cecal lengths in mice inoculated with saline (Control); infected with Map only (Map 
only); inoculated with saline and treated with DSS (DSS only); and mice infected with Map 
and treated with DSS (Map + DSS). The average cecal length in Map + DSS mice was 
shorter relative to all other treatment groups (**, p < 0.0001).  The average cecal length for 
DSS only mice was shorter relative to the control and Map only mice (*, p < 0.03).  Data are 
represented as the mean ± standard error of the means from three separate experiments 
including 22 DSS only mice, 25 Map + DSS mice, 8 Map only and 9 control mice.  
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Figure 4. Representative photomicrographs of ceca from Map + DSS (A), Map only (B), 
DSS only (C) and Control (D) mice. Note the ulceration of the mucosa and the cecal lumen 
containing neutrophils intermixed with blood in the Map + DSS mouse. There is moderate 
hyperplasia and submucosal edema in the DSS only mouse. Lesions were not identified in 
the mucosa of the DSS only and Control mice. HE; Bar = 100 µm.   
A B 
C D 
86 
 
 
Fig. 5. Cecal histologic lesion scores in mice inoculated with saline (Control); infected with 
Map only (Map only); inoculated with saline and treated with DSS (DSS only); and mice 
infected with Map and treated with DSS (Map + DSS). Cecal lesion scores were significantly 
higher in Map + DSS mice relative to all other treatment groups (*, p < 0.0013). Data are 
represented as the mean ± standard error of the means from three separate experiments 
including 22 DSS only mice, 25 Map + DSS mice, 8 Map only and 9 control mice.  
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Fig. 6. Log colony forming units per gram of tissue in mice infected with K10 Map and 
given either DSS or water. A greater concentration of K10 Map was isolated from the small 
intestine from Map K10 only mice relative to Map K10 + DSS mice (*, p = 0.043). 
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Abstract 
Microbial pathogens have been linked to reactivation or exacerbation of inflammation 
in IBD patients. However, only a limited number of studies have examined the role of 
specific pathogens as a cause of enhanced intestinal inflammation; while fewer studies have 
examined the role of occult infections in the development of intestinal inflammation. We 
have previously demonstrated that subclinical and persistent enteric mycobacterial infection 
sensitizes BALB/c mice to enhanced intestinal injury. Our primary aims for this study were 
to define the intestinal and systemic immune cytokine profiles in our Map enhanced 
intestinal injury model and to determine if Map infected mice had an antigen specific 
immune response. To address these aims, we analyzed adaptive and/or innate cytokine 
expression patterns in the intestines and spleen and evaluated mice for Map specific 
antibody. We also infected a subset of SCID/C.B-17 (SCID) mice with Map and treated them 
with DSS to determine if Map enhanced intestinal disease is independent of the adaptive 
immune response. BALB/c mice infected with Map had antigen specific production of IgG2a 
and IgG1 antibody and Map specific IFNγ and IL-17 production from cells isolated from the 
spleen. In mice infected with Map and treated with DSS we did not observe an increase in 
intestinal IFNγ, IL-17 or IL-4 mRNA, or an increase in Map-specific production of the same 
set of cytokines in cells isolated from the cecal tonsil. However, Map infected and DSS 
treated mice had increased expression of IL-1β.  Similar to BALB/c mice, SCID mice treated 
with DSS and infected with Map had enhanced clinical disease and increased intestinal 
expression of IL-1β; but, unlike BALB/c mice, had enhanced TNF-α expression. In 
conclusion, our results confirm that Map infected mice had an antigen specific immune 
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response and that Map enhanced intestinal disease is associated with increased activation of 
the innate immune response. 
Key words: Dextran sulfate sodium, IL-1β, Mycobacterium avium subsp. paratuberculosis, 
subclinical infection, enhanced inflammation   
Introduction 
Acute exposure to various environmental factors may be associated with the periods 
of reactivation or exacerbation of inflammation in both patients with IBD and in 
experimental animal models of intestinal inflammation. For example, the administration of 
iron has been associated with relapse of IBD and has been shown to exacerbate dextran 
sulfate sodium (DSS) mediated intestinal inflammation.[1, 2] Moreover, acute exposure to an 
adherent-invasive strain of Escherichia coli (AIEC) can enhance experimental intestinal 
inflammation.[3]  However, these models do not address the question of how chronic and 
subclinical microbial infection influences mucosal homeostasis, and inflammation in IBD. 
Both enhanced activation of the adaptive and innate immune response are thought to 
play an important role in the pathogenesis of IBD.[4] In terms of the adaptive immune 
response, Crohn’s disease (CD), a clinical phenotype of IBD, is defined by a polarized Th1 
immune response with increases in IFNγ and IL-12.[4] The adaptive immune response can 
also be amplified in experimental models of IBD where it has been shown that infection with 
Hymenolepis diminuta increases IL-4 expression in the TNBS model of colitis.[5] The 
importance of the innate immune response is highlighted by the success of anti-TNF-α 
therapy in the treatment of CD.[6] Moreover, other cytokines of the innate immune system, 
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such as IL-1β, are thought to play an important role in the pathogenesis of IBD as evidenced 
by its increase in the inflamed mucosa from patients with CD.[7, 8]  Although adaptive and 
innate cytokines are elevated in IBD, it is not clear how an underlying infection with an 
opportunistic pathogen; in particular, one that targets macrophages, influences the 
characteristic immunopathology in IBD.   
We have previously reported that subclinical and persistent mycobacterial infection in 
BALB/c mice exacerbates subsequent DSS mediated intestinal inflammation, as 
demonstrated by enhanced clinical disease, exacerbation of gross lesions and increased lesion 
scores. In this study we set out to define the intestinal and systemic immune profiles in our 
Map enhanced intestinal injury model. We hypothesized that an additive Th1 immune 
response was associated with Map enhanced intestinal inflammation. Our rationale for this 
hypothesis was that acute DSS mediated colitis in the BALB/c mouse is defined by a Th1 
cytokine profile and because Map infected macrophages is capable of producing a similar 
profile of cytokines.[9, 10] To address our goal, we analyzed adaptive and innate intestinal 
and systemic cytokine expression patterns and evaluated mice for Map antigen specific 
antibody. We next infected a subset of SCID/C.B-17 (SCID) mice with Map to determine if 
enhanced intestinal disease would occur in the absence of an adaptive immune response. Our 
results demonstrate that Map enhanced intestinal inflammation is associated with increased 
activation of the innate immune response; in particular, expression of IL-1β. 
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Materials and methods 
Animals  
Conventionally reared 6-8 week-old male BALB/c and C.B-17 scid (SCID) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME), weighed approximately 22-
24 grams, and were housed in micro-isolation units that were individually ventilated in a 
positive pressure Thoren unit caging system at the Iowa State University College of 
Veterinary Medicine biosafety level II animal care facility. All animal experiments were 
approved by the Institutional Animal Care and Use Committee of Iowa State University. 
Bacterial inoculum and infection 
The Map strain K10 was a field isolate obtained from the National Animal Disease 
Center (Ames, IA) and maintained at 37°C in Middlebrook 7H9 broth supplemented with 
mycobactin J. Logarithmic growth-phase bacteria were washed and resuspended in sterile 
saline for inoculation. Bacterial concentration was determined by measuring at 540 nm, 
comparing the absorbance optical density to the standard curve and adjusted to a final 
concentration of 1x109 colony-forming units/ml. Controls were given a sham inoculation of 
saline. The Map inoculum used in these studies was shown to have greater than 90% viability 
via fluorescein diacetate staining and flow cytometry analysis prior to inoculation. In 
addition, challenge inocula were confirmed negative for contaminants by streaking onto 
sheep blood agar plates 24 h prior to inoculation.  
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Experimental design  
Tissues from BALB/c utilized in this study were part of a previously reported 
experiment (Chapter 2) in which three separate experiments were conducted with 10-11 mice 
per treatment group. Two separate experiments were performed with SCID mice, with 4-5 
mice per treatment group.  In all experiments, mice were assigned to one of two groups and 
either given a single intraperitoneal sham injection of saline or Map. Following inoculation, 
body weights of the mice were measured at weekly intervals and feces were periodically 
collected for isolation of Map. At approximately 3 months post-inoculation, acute intestinal 
injury was chemically induced by administering a suboptimal concentration of 2% dextran 
sulfate sodium (DSS; MP Biomedicals, Solon, OH) in the drinking water for 6 days. We 
established this dose by determining the lowest DSS concentration in the drinking water that 
would induce minimal but perceptible microscopic lesions in the cecal and colonic mucosa. 
Using a pilot study we tested doses that ranged from 1-5% DSS, increasing by 0.5% DSS in 
each treatment group. 2% DSS induced consistent mild multifocal villus elongation with 
minimal erosions of the mucosal epithelium. This dose was selected for all experiments in 
this study.  While the mice were administered DSS, they were weighed daily and on day 6 all 
of the mice were euthanized with CO2 and necropsies were preformed. At necropsy, body 
weights and colon and cecal length were measured. Additionally, sections of spleen, liver, 
small and large intestine, and mesenteric lymph node were collected for histopathology 
and/or isolation of Map.  
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Histopathology 
At necropsy, samples of liver, spleen, small and large intestine, and mesenteric lymph 
node were fixed in 10% neutral buffered formalin, processed by routine methods, embedded 
within paraffin wax and sectioned. Sections of tissue (5 µm) were stained with hematoxylin 
and eosin. Cecal histologic lesion scores were generated on the severity of mucosal epithelial 
erosion and hyperplasia, the degree of lamina propria inflammatory cell infiltrate, and edema 
(Table 1).   
Acid-fast staining (Ziehl-Neelsen method) 
Slides were deparaffinized and rehydrated in distilled water. Carbol fuchsin solution 
was added for 45 seconds while microwaving at 450 W. Slides were rinsed in 0.5% acid 
alcohol for decolorization, rinsed for 10 minutes in tap water then counterstained in 
methylene blue for 10 minutes. 
Culture of M. avium subsp paratuberculosis from tissues and feces  
Sections of spleen, liver, and small and large intestine were collected for isolation of 
Map. Each piece of tissue was weighed and homogenized in 0.75% hexadecylpyridinium 
chloride solution and allowed to stand overnight at room temperature to decontaminate the 
cultures. Sediments from individual tissue homogenates (100 μl) were inoculated onto 
Middlebrook 7H10 agar.  Additionally, the peritoneum was washed with saline and 100 μl 
was plated onto Middlebrook 7H10 agar. After 12 weeks of incubation at 37°C, individual 
colonies were counted. Fecal pellets were collected from each group mice at approximately 
10-14 day intervals until the end of the experiment. The fecal pellets were homogenized in 1 
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ml of 0.05% Tween 80, diluted, decontaminated and plated on supplemented 7H10 agar as 
described above.  
Preparation of Map antigen 
Map was cultured in Middlebrook 7H9 broth at 37°C supplemented with mycobactin 
J.  The bacterial concentration was determined by measuring at 540 nm, comparing the 
absorbance optical density to the standard curve. Bacteria were pelleted by centrifugation at 
3500g for 20 minutes and subsequently washed twice with PBS. The pellet was then 
resuspended in PBS and sonicated on ice with a probe sonicator. Sonication consisted of 
three cycles of 10 minute bursts at 18W (amplitude 60%) on ice with 10 minute chilling 
periods between sonication steps.  Debris was removed by centrifugation at 12000g for 5 
minutes.  The supernatants were saved and stored at -70°C until used. The protein 
concentration of the supernatant was determined by using the BCA protein assay (Thermo 
Scientific, Rockford, IL). Additionally, the supernatant was confirmed negative for 
contaminants by streaking onto a sheep blood agar plate.  
Map-specific antibody detection by ELISA.  
Map-specific IgG1 and IgG2a antibody responses in the sera of BALB/c mice 
infected with Map or sham inoculated with saline were measured by ELISA. Briefly, 96-well 
Immulon 2HB microtiter plates (Fisher Scientific, Hanover Park, IL) were coated with 2.5 
µg/ml of Map K10 sonicate in coating buffer (sodium carbonate-bicarbonate buffer) 
overnight at 4°C. Plates were washed two times and blocked with 1% BSA in TBS (Tris 
buffered saline) for 2 h at room temperature. Plates were then washed four times and 
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individual serum samples diluted at 1:100 in sample diluent (TBS/Tween 20/BSA) were 
added. After 1 h of incubation at room temperature, the plates were washed four times, and 
the concentrations of IgG subclass antibodies were determined following the addition of 
avidin-horseradish peroxidase detection antibody, goat anti-mouse IgG1 (Bethyl Laboratories 
Inc., Montgomery, TX) at 1:150,000 or goat anti-mouse IgG2a (Bethyl Laboratories Inc., 
Montgomery, TX) at 1:50,000 for 1h at room temperature. The plates were then washed five 
times and TMB substrate was added for 12 minutes. Stop reagent was then added and plates 
read at 450nm to obtain OD values.    
Spleen and cecal tonsil cell isolation 
Cells isolated from the spleen and cecal tonsil from a total of 6 mice per group was 
individually analyzed for the production of Map-specific IFNγ, IL-4, and IL-17. At day 6 of 
DSS administration mice were euthanized with CO2 inhalation and their spleens and cecal 
tonsils were aseptically removed and transported in RPMI 1640 for cell isolation. Single cell 
suspensions were obtained by homogenization.  Cells were then washed, resuspended in 
culture medium and counted, with more than 90% cell viability via trypan blue exclusion. 
Complete medium was prepared by adding 10% fetal bovine serum, 0.5 mM 2-
mercaptoethanol, penicillin G (100U/ml), streptomycin (100 µg/ml), amphotericin B (250 
ng/ml), 2 mM L-glutamine, and gentamicin (25 µg/ml) to RPMI 1640 medium. Spleen and 
cecal tonsil cells were incubated at 1 x 106 cells/ml and 1 x 105 cells/ml, respectively. Cells 
were stimulated with either Map antigen (10 µg/ml), concanavalin A (5 µg/ml; ConA; 
Sigma, St. Louis, MO), or medium alone and maintained at 37°C, 5% CO2 for 3 days, with 
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cell culture supernatants from duplicate wells being collected and stored at -70°C until 
analyzed.  
Cytokine ELISA  
Commercially available ELISA kits (eBioscience, San Diego, CA) were used for the 
detection of IL-4, IFN-γ, and IL-17 protein in splenic and cecal tonsil cell culture 
supernatants. The appropriate recombinant cytokine protein was used as a positive control to 
generate the standard curve.  The detection limit was 4 pg/ml, 15 pg/ml, and 4 pg/ml for IL-
4, IFN-γ, and IL-17, respectively. Results are expressed as the mean (± SEM) pg/ml, 
calculated from 2-3 mice per group from two separate experiments and tested individually. 
Quantitative real-time reverse transcriptase PCR (qRT-PCR)  
Samples of cecum from each treatment group of mice were analyzed for the 
expression of a panel of cytokines (Table 2). The primer sequences were designed by using 
Primer Express Software (Applied Biosystems, Foster city, CA). Possible genomic DNA 
contamination in the RNA samples was eliminated by using Turbo DNA-free (Ambion, 
Austin, TX). A SuperScript III first-strand synthesis system for RT-PCR (Invitrogen, 
Carlsbad, CA) was used for cDNA synthesis. A Sybr green PCR system (Applied 
Biosystems, Foster city, CA) was used in the two-step real-time PCR, and the signal was 
detected by using a GeneAmp 5700 sequence detection system. Prior to final qRT-PCR 
sample analyses, a test plate was run using a mixture of cDNA samples serially diluted for 
each target of interest to identify the specific cDNA sample dilution range at which qRT-
PCR inhibition no longer existed; and the extended dilution range of the standard curves 
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within which all targets exhibited amplification efficiencies between 80 and 100%. cDNA 
samples were diluted to their ideal concentration when added to the final reaction mixtures 
for qRT-PCR. The Ct values were gathered at an appropriate threshold for each different 
target using the GeneAmp 5700 SDS software, and relative quantitative analysis was 
performed using our own custom Excel files. Relative mRNA expression quantity for each 
qRT-PCR target was calculated using the equation: relative quantity = 10 (Ct-b)/m. Relative 
quantity values for each target were calculated using the slope (m) and y-intercept (b) of the 
line generated for each target’s standard curve. Final relative values were normalized to beta 
actin and dissociation curve analysis was conducted as a control for each target gene.  
Statistical analysis 
Changes in body weight were analyzed using an ANOVA model with repeated 
measures. Map infection or saline inoculation, DSS or water administration, day and their 
interactions were considered as fixed effects, with animal being the subject of repeated 
measures.  On each day, the treatment group means were compared first with an overall F-
test and then followed by post-hoc Tukey-Kramer’s t-test for multiple comparisons if the F-
test was significant. A p-value of < 0.05 was considered significant. For all other parameters, 
treatment group means were compared first with an overall F-test and then followed by post-
hoc Student’s t-test with group mean differences considered significant if the p-value was 
<0.05. Data are presented as the mean value ± standard error of the mean except where stated 
otherwise.  
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Results 
Cecal cytokine gene expression in BALB/c mice 
To determine if there were unique cytokine profiles in the ceca of the different 
treatment groups of BALB/c mice, we used qRT-PCR to evaluate the gene expression of a 
panel of cytokines associated with the adaptive and innate immune response. Cecal 
homogenates from Map + DSS mice had a significant increase in the expression of IL-1β 
(Fig.1,**, p < 0.016); however, they did not have a significant increase in the expression of 
any of the markers of the adaptive immune response, namely, IFNγ, IL-4 or IL-17 (Fig. 2). In 
contrast to the Map + DSS mice, DSS only mice had a significant increase in the expression 
of TNF-α (Fig. 1,***, p < 0.016), IL-4 and IFNγ (Fig. 2 *, **, p < 0.013 and p < 0.001, 
respectively). The expression of all innate cytokines in the Map + DSS and DSS only groups 
was higher relative to their respective controls (Fig. 1, *, p < 0.0004).  Control and Map only 
mice did not have a significant increase in the expression of any of the cytokines evaluated. 
All data from each individual animal were normalized to the data for the internal control β-
actin, which was expressed at similar levels within each treatment group. 
Cytokine production from cells isolated from the spleen and cecal tonsil 
In addition to evaluating cytokine expression by qRT-PCR, we performed ELISA 
assays to determine if there was antigen specific production of IFNγ, IL-4 and IL-17 by 
measuring cytokine secretion from cells isolated from the spleen and cecal tonsil. We chose 
to isolate cells from the cecal tonsil because it is thought to play an essential role in the 
development of DSS mediated intestinal inflammation.[11] Cells isolated from the spleens of 
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Map + DSS and Map only mice had a significant increase in the production of antigen-
specific IFNγ (Fig. 3, *, ** p < 0.0001). Additionally, Map + DSS mice had a significant 
increase in the production of IL-17 (Fig. 4, *, p < 0.009). Production of antigen-specific IL-4 
was not different for any of the treatment groups (Fig. 5). In contrast to the spleen, there was 
not antigen-specific production of any of the cytokines in cells isolated from the cecal tonsil 
in mice infected with Map, regardless of whether they were given DSS or not. Control and 
DSS only mice did not produce antigen-specific IFNγ, IL-4, or IL-17. 
Map specific antibody responses 
We wanted to determine if mice infected with Map had Map antigen specific 
antibody responses and assess whether the response was associated with a Th1 or Th2 
polarized immune response by measuring antigen-specific IgG1 and IgG2a antibody. To 
accomplish this we collected blood at day 6 of DSS treatment and analyzed the serum by 
ELISA. Both Map + DSS and Map only mice produced antigen specific IgG1 and IgG2a 
compared to the control and DSS only mice (Fig. 6, *, **, *** p < 0.0001). Map-specific 
IgG1 and IgG2a antibody responses were decreased in those mice treated with DSS, with the 
decrease being statistically significant for Map specific IgG2a  (**, p = 0.0005). Antigen- 
specific antibody was not detected in the DSS only and control mice. 
Clinical disease, gross pathology, cecal histologic lesion scores in SCID mice  
Results of clinical disease, gross pathology and histologic lesion scores for BALB/c 
mice were reported previously (Chapter 2). In order to establish Map infection in SCID mice, 
one of two groups was inoculated with 1 x 108 CFU of Map strain K10 or a separate group 
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was given a sham inoculation of saline by a single intraperitoneal injection. Mice infected 
with Map transiently lost up to 0.5 grams of their body weight within the first 7 days after 
inoculation relative to sham inoculated mice (data not shown). However, mice regained the 
weight they had lost and by the end of the incubation period all treatment groups had similar 
body weights. Other than transient weight loss, inoculation with Map did not cause signs of 
clinical disease.   
In DSS treated mice, to evaluate clinical disease we monitored body weight and rectal 
bleeding. Significant weight loss was identified in the Map + DSS SCID mice and occurred 
on days 5 and 6 of DSS administration. At day 6 Map + DSS lost more weight relative to all 
other treatment groups (Fig. 7, *, p < 0.03), while at day 5 they had lost more weight 
compared to the Control and Map only groups (Fig. 7, *, p < 0.05). DSS only mice lost more 
weight relative to the control at day 5 (Fig. 7, **, p < 0.04). Rectal bleeding (Table 3) 
occurred only in treatment groups given DSS and coincided with onset of weight loss. There 
was a greater frequency of rectal blood in Map + DSS mice; 100% of Map + DSS mice had 
rectal blood compared to 50% of DSS only mice.  
A consistent feature in the murine DSS colitis model is cecal and colonic shortening 
(atrophy) and this was used as a measure of gross pathology in this model.[12] Cecal atrophy 
was most severe in the Map + DSS group (Fig. 8, *, p < 0.001) compared to all other 
treatment groups. Map only mice had cecal lengths similar to the negative control.  We 
observed similar trends in the colon for gross and histologic lesions, with significant 
shortening of the colon in Map + DSS mice compared to all other treatment groups; however, 
102 
 
we chose to focus our analysis on the cecum because it had more severe and consistent 
lesions.   
Microscopic lesions were typical of the DSS mucosal injury model and were defined 
by a multifocal proliferative to ulcerative typhlitis and colitis. In the DSS only group there 
was mild multifocal gland proliferation and rare mucosal ulceration. The histologic score was 
significantly higher between the DSS only and the control group (Fig. 9, *, p = 0.02). In 
contrast, the lesions were more severe and widespread in the Map + DSS group (**, p < 
0.0001).  The control and Map only mice had similar cecal lesion scores.    
M. avium subsp. paratuberculosis tissue colonization 
The distribution of Map in tissues was similar to that reported previously for SCID 
mice.[13] Map was isolated from spleen, liver, peritoneum, and small and large intestines 
from mice infected with Map, with the greatest concentration of bacteria being isolated from 
the spleen and being too numerous to count (Fig.10). Map was not isolated from any tissues 
from the uninfected control animals. DSS administration did not have a significant effect on 
bacterial load in any of the tissues; however, there was a trend for decreased bacteria in the 
small intestines of Map + DSS mice, but this did not reach statistical significance. Map was 
not isolated from the feces from any of the treatment groups. 
Acid-fast stains of tissues  
 Acid-fast bacilli were present within foci of granulomatous inflammation in the liver, 
spleen, peritoneum, cecum, and small intestine. Consistent with the isolation results there 
was a greater density of acid-fast bacilli in the spleen, liver, and at the site of inoculation in 
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the peritoneum compared to the small and large intestine. In all tissues examined acid-fast 
bacilli  were identified within aggregates of cells with macrophage-like morphology.   
Cecal cytokine gene expression in SCID mice 
To determine if the innate cecal cytokine pattern was similar to BALB/c mice, we 
used qRT-PCR to evaluate cecal gene expression. Cecal homogenates from Map + DSS mice 
had a significant increase in the expression of IL-1β (Fig. 11,*, p < 0.0009) and TNF-α (**, p 
< 0.0062). As expected there was no expression of markers of the adaptive immune response, 
namely, IFNγ, IL-4 and IL-17. Control and Map only mice did not have a significant increase 
in the expression of any of the cytokines evaluated. All data from each individual animal 
were normalized to the data for the internal control β-actin, which was expressed at similar 
levels within each treatment group. 
Caspase-1 Expression 
Considering the high expression of IL-1β in both BALB/c and SCID mice infected 
with Map and given DSS, we wanted to determine if caspase-1 expression, which is 
necessary for the processing of IL-1β from pro-IL-1β to mature IL-1β, was increased. There 
was a significant increase in the expression of caspase-1 in Map + DSS BALB/c mice (Fig. 
12, **, p < 0.0001). There was a similar trend in the Map + DSS SCID mice, but this 
increase was not statistically significant. In SCID mice, DSS only mice had a significant 
increase in the expression of caspase-1 (Fig. 12, *, p < 0.0004). Control and Map only SCID 
and BALB/c mice had a similar level of caspase-1 expression. 
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Discussion 
We have previously shown that persistent enteric mycobacterial infection sensitizes 
BALB/c mice to enhanced acute mucosal injury. The results from the current study 
demonstrate that Map infected mice developed a systemic antigen specific immune response. 
However, enhanced sensitivity to DSS was independent of adaptive immune cytokines, 
which is supported by the sensitivity of Map infected SCID mice to DSS.  A common feature 
when BALB/c and SCID mice were used in this model was increased expression of IL-1β. 
Collectively, these results indicate that Map enhanced intestinal injury is not dependent on 
the adaptive immune response but is associated with increased activation of the innate 
immune response.  
Mycobacterium avium ss. paratuberculosis, an intracellular pathogen of 
macrophages, is an appropriate model organism that can be utilized to determine if a 
subclinical and chronic infection can sensitize or prime the mucosa for an aberrant immune 
response following injury to the intestinal mucosa.[14] Other investigators and our lab have 
previously demonstrated that Map is capable of establishing subclinical and persistent 
intestinal infection in the BALB/c mouse.[15] This is relevant because Map has been 
proposed to act as an immunomodulating factor in CD.[16]  
Map infection in the BALB/c mouse results in an antigen-specific immune 
response.[17] Likewise, in Map infected mice we observed splenic antigen specific IFNγ and 
IL-17. Splenic production of Map-specific IFNγ has been reported previously in the BALB/c 
mouse.[18] However, Map antigen specific IL-17 has not been described, although Map 
specific T-cell clones have been isolated from patients with CD that produce IL-17.[19] Even 
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though there was a trend for increased IL-4, it did not reach statistical significance.  
However, despite an immune response to Map, infection did not result in detectable clinical 
disease in our model. This model may certain aspects of “occult” infections by weak 
pathogens, including M. avium, in predisposed individuals. To further define the antigen 
specific immune response, we also measured Map specific antibody production.  We 
observed both antigen specific IgG2a and IgG1 antibodies in Map infected mice. This is 
consistent with previous vaccine studies in C57/BL6 or BALB/c mice.[17, 20] The 
predominance of IFNγ produced in cells isolated from the spleen relative to IL-4 is consistent 
with IgG2a production.[21] However, we also observed significant, but not greater, 
production of IgG1. A trend towards IgG1 production in the Th2 prone BALB/c mouse may 
be expected but we did not observe increased expression of IL-4 in either the intestine or 
spleen.[22] This is consistent with previous studies where low splenic expression of IL-4 was 
demonstrated in Map infected mice.[20] We cannot exclude the possibility that there was an 
increase in other cytokines associated with IgG1 production, such as IL-5 and IL-6.[23, 24] 
An unanticipated observation was a decrease in both IgG1 and IgG2a in mice infected with 
Map and given DSS. This may be associated with protein loss through the areas of intestinal 
ulceration; however, to confirm this possibility serum protein levels will need to be 
measured. In total, these observations establish that Map infected mice had an antigen 
specific immune response. However, a polarized immune bias was not clearly demonstrated. 
Mice had both antigen specific IgG2a and IgG1 production despite the marked increase in 
antigen specific IFNγ.  
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We observed divergent adaptive and innate immune cytokine profiles in the cecal 
homogenates of mice infected with Map and/or exposed to DSS. We had hypothesized that 
the combination of Map infection and exposure to DSS would result in amplification of 
adaptive immune cytokines; yet increased IL-4 and IFNγ expression was restricted to mice 
treated with DSS only. Although increased expression of IFNγ is associated with short term 
DSS treatment in the BALB/c mouse, enhanced IL-4 expression is not characteristic; 
however, its increase has been reported previously in BALB/c mice treated with DSS 
alone.[9, 25] Furthermore, it has been proposed that a Th2 immune response is protective in 
the DSS mediated model of colitis.[26]  
To assess if mice had an intestinal antigen-specific immune response we evaluated 
cells isolated from the cecal tonsil because it plays an important role in DSS mediated 
intestinal inflammation, as demonstrated by amelioration of disease following its 
removal.[11] Additionally, it is the cecum where we saw the most consistent and severe 
lesions. In agreement with the gene expression data, we did not demonstrate cecal antigen 
specific production of IFNγ, IL-17 or IL-4 in Map infected mice. We cannot exclude the 
possibility that there was increased expression of the immunoregulatory cytokines IL-10 and 
TGF-β or cytokine independent mechanisms involved, for example CTLA-4 dampening the 
adaptive immune response.[27] Only one other study, to the authors’ knowledge, has 
evaluated cytokine expression in the intestines of mice exposed to Map. That study utilized 
IL-10 deficient mice on a B6 background that develop spontaneous colitis under 
conventional housing conditions.[28] The author’s demonstrated an increase in IFNγ positive 
CD4+ T-cells and NK/NKT cells in the intestinal mucosa of mice exposed to live Map. There 
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are some distinct differences between these two models. For example, intestinal colonization 
was not demonstrated in the IL-10 deficient mice and these mice lack IL-10 an essential 
immunoregulatory cytokine, a cytokine which may have played a role in our model. Lastly, 
differences in these two models may be associated with the inherent Th1/Th2 immune biases 
of these two inbred strains of mice.[22] 
Enhanced innate immune activation with increases in IL-1, TNF-α and IL-6 is also a 
feature of acute DSS exposure in the BALB/c mouse.[9, 29] We identified increased 
expression of a similar panel of cytokines in mice given DSS alone. However, superimposed 
intestinal injury in Map infected mice generated a unique cecal cytokine profile. These mice 
had augmentation of the innate immune response, as indicated by increased cecal expression 
of IL-1β which was dependent on injury to the intestinal mucosa. Generation of mature IL-1β 
requires processing by  caspase-1, whose activation is mediated by the inflammasome.[30] 
We observed increased expression of caspase-1 in Map infected mice given DSS which, 
similar to IL-1β, was dependent on injury to the mucosal barrier. Map infected macrophages 
may have directly generated IL-1 or contributed through increased recruitment of 
neutrophils, which are able to produce caspase-1 and IL-1β following exposure to LPS.[31] 
By analogy, Mycobacterium tuberculosis infected mouse macrophages are capable of 
recruiting neutrophils via the production of KC, a neutrophil chemoattractant.[32].   
To confirm that Map enhanced intestinal inflammation was independent of the 
adaptive immune response; we infected a subset of SCID mice. Our results show that Map 
infected and DSS treated SCID mice had a similar disease phenotype as the BALB/c mice. 
They had more severe clinical disease, exacerbation of gross lesions, and increased cecal 
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lesion scores relative to all of the other treatment groups.  Furthermore, similar to our 
observation in the BALB/c mice, Map infected and DSS treated SCID mice had increased 
expression of both IL-1β and caspase-1. However, ceca from these mice also had increased 
expression of TNF-α, the increase of which was dependent on exposure to DSS. This is 
consistent with in vitro data that demonstrates LPS primed Map infected macrophages 
produce increased amounts of TNF-α.[33] Differences in bacterial burden, which was higher 
in SCID mouse intestines, may influence TNF-α expression [34, 35] Similar to the BALB/c 
mice, there was also increased expression of caspase-1 in SCID  Map infected and DSS 
treated mice; however, caspase-1 expression was greater in DSS only treated SCID mice. 
This may reflect differences in the character of the lesions, for example the rate of apoptosis 
or temporal variations in caspase-1 expression in the two groups of mice.[36] Collectively, 
the data from both the SCID and BALB/c mouse studies suggests that Map enhanced 
intestinal inflammation is independent the adaptive immune response and is associated with 
innate immune activation. 
Although the disease phenotype was similar for both the SCID and BALB/c Map 
infected and DSS treated mice, suggesting that there was a common pathway, perhaps 
mediated by IL-1β, for the development of the lesions in these two models, we recognize that 
there may be mechanistic differences resulting in the same outcome. For example, we cannot 
rule-out that enhanced disease in BALB/c mice was mediated by an increased antibody 
response to the commensal flora, which has been demonstrated in Helicobacter bilis and 
cytomegalovirus models of IBD.[37, 38] Furthermore, we cannot exclude the possibility that 
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disruption of regulatory T-cell function was a feature of Map enhanced disease in the 
BALB/c mouse.    
In conclusion, we have shown that Map infected mice have an antigen specific 
immune response and that Map infection in combination with DSS treatment results in a 
distinct cytokine profile relative to mice infected with Map only or treated with DSS alone. 
We believe our model can be utilized to better understand how a persistent infection with a 
low-level microbial pathogen, such as Map, disrupts the regulation of intestinal homeostasis 
and predisposes the host to enhanced intestinal injury and inflammation. Future studies will 
try and define a mechanism for how infection with Map promotes increased innate immune 
activation, with an emphasis on understanding how Map infection alters IL-1β production.   
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Table 1  
Cecal lesion scoring system 
 
Parameters     Scoring Criteria 
Enterocyte hyperplasia    Ratio of crypt depth to width 
Rising score from 0 to 3 (no hyperplasia  severe hyperplasia) 
Inflammatory score                     Denotes cellular infiltrates in the lamina propria or cellular 
exudates overlying areas of mucosal ulceration 
Rising score from 0 to 3 (small  large numbers of inflammatory 
cells)  
Mucosal erosions  Rising score from 0 to 3 (no erosions  ulceration) 
Edema     Rising score from 0 to 3 (no edema  marked submucosal edema) 
Distribution   Rising score from 0 to 3 
  (0 = lesion is not present; 1 = < 25%; 2 = 25 – 75%; and 3 = > 75% of the section is affected) 
 
Parameters are scored (0  3) + distribution (0  3) resulting in a maximal total histological score of 
24. 
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                                                      Table 2. Primer sequences for qRT-PCR 
        Primer       
                               
GenBank 
Gene product  Sense      Antisense           Accession no. 
β-actin          ACGGCCAGGTCATCACTATTG     CCAAGAAGGAAGGCTGGAAAA       NM_007393 
IL-1α          AGCCTTATTTCGGGAGTCTATTCA    AGTGACTCAGGGTGAGGAAGGTT   NM_010554 
IL-1β         GTCACAAGAAACCATGGCACAT     GCCCATCAGAGGCAAGGA          NM_008361 
IL-4         GGCATTTTGAACGAGGTCACA     AGGACGTTTGGCACATCCA          NM20572 
IL-6         ATCCGCGACGTGGAACTG     ACCGCCTGGAGTTCTGGAA          NM_031168 
IL-17         TCATCTGTGTCTCTGATGCTGTTG     TCGCTGCTGCCTTCACTGT           NM_010552 
IFN-γ     ACAATGAACGCTACACACTGCAT     TGGCAGTAACAGCCAGAAACA          NM_008337 
TNF-α          TGGGACAGTGACCTGGACTGT     AGTGAATTCGGAAAGCCCATT           NM_013693 
Caspase-1       AAGAATCAT TTCCGCGGT TG     AGGATCTTGTCAGCCATGGC              NM_009807 
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Table 3. 
                  
            Treatment                         Severity of Rectal Blood                    % with Rectal Blood 
 
Map only 
-                                                  0% 
 
DSS only 
                  +                                               50% 
 
Map + DSS 
               ++/+++                                        100% 
 
Severity and % of rectal blood in SCID mice infected with Map or inoculated with saline 
after the administration of DSS or water. A greater percentage of Map K10 + DSS mice had 
rectal blood compared to all other treatment groups.  Data are from two separate experiments 
including 6 Map + DSS mice, 4 Map only and 4 DSS only mice.  
 
 
 
116 
 
 
Fig.1   Cecal cytokine mRNA expression in BALB/c mice inoculated with saline (Control); 
infected with Map only (Map only); inoculated with saline and treated with DSS (DSS only); 
and mice infected with Map and treated with DSS (Map + DSS). IL-1β mRNA expression 
was significantly increased in Map + DSS treated mice relative to all other treatment groups 
(**, p < 0.016). The expression of TNF-α was significantly elevated in DSS only mice 
compared to all other groups (***, p < 0.016). Furthermore, the expression of all cytokines in 
the Map + DSS and DSS only groups was higher relative to their respective controls (*, p < 
0.0004).  Data are represented as the mean ± standard error of the means from one of two 
separate experiments, including 7 Map + DSS mice, 2 Map only, 5 DSS only mice and 2 
control mice. β-actin was used as an internal control, with target gene mRNA expression 
being normalized to β-actin mRNA within the same tissue.  
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Fig. 2   Cecal cytokine mRNA expression in BALB/c mice inoculated with saline (Control); 
infected with Map only (Map only); inoculated with saline and treated with DSS (DSS only); 
and mice infected with Map and treated with DSS (Map + DSS). IL-4 and IFNγ mRNA 
expression was significantly increased in DSS only treated mice relative to all other 
treatment groups (*, **, p < 0.013 and p < 0.001, respectively). Data are represented as the 
mean ± standard error of the means from one of two separate experiments, including 7 Map + 
DSS mice, 2 Map only, 5 DSS only mice and 2 control mice. β-actin was used as an internal 
control, with target gene mRNA expression being normalized to β-actin mRNA within the 
same tissue.  
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Fig. 3  Induction of IFNγ following stimulation of spleen cells with Map sonicate from 
BALB/c mice inoculated with saline (Control); infected with Map only (Map only); 
inoculated with saline and treated with DSS (DSS only); and mice infected with Map and 
treated with DSS (Map + DSS). IFNγ secretion was significantly higher in Map + DSS  and 
Map only mice stimulated spleen cells mice relative to all other treatment groups (*, **,  p < 
0.0001). Data are represented as the mean ± standard error of the means from two separate 
experiments including 4 Map + DSS mice, 2 Map only, 4 DSS only mice and 2 control mice.  
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Fig. 4  Induction of IL-17 following stimulation of spleen cells with Map sonicate from 
BALB/c mice inoculated with saline (Control); infected with Map only (Map only); 
inoculated with saline and treated with DSS (DSS only); and mice infected with Map and 
treated with DSS (Map + DSS). IL-17 secretion was significantly higher in Map + DSS 
stimulated mice relative to all other treatment groups, with the exception of the Map only 
stimulated mice (*, p < 0.009). Data are represented as the mean ± standard error of the 
means from two separate experiments including 4 Map + DSS mice, 2 Map only, 4 DSS only 
mice and 2 control mice.  
 
0
50
100
150
200
250
unstim stim unstim stim unstim stim unstim stim
Control DSS only Map only Map + DSS
IL
-1
7 
pg
/m
L
*
120 
 
 
Fig. 5 Induction of IL-4 following stimulation of spleen cells with Map sonicate from 
BALB/c mice inoculated with saline (Control); infected with Map only (Map only); 
inoculated with saline and treated with DSS (DSS only); and mice infected with Map and 
treated with DSS (Map + DSS). There are no statistically significant differences in IL-4 
secretion between any of the treatment groups. Data are represented as the mean ± standard 
error of the means from two separate experiments including 4 Map + DSS mice, 2 Map only, 
4 DSS only mice and 2 control mice.  
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Fig. 6  Measurement of serum IgG1 and IgG2a antibody responses to whole cell sonicates of 
Map in BALB/c mice. The magnitude of the antibody response was determined by ELISA as 
described in Section 2. The average OD value is significantly higher for both IgG1 and 
IgG2a in mice infected with Map only and Map + DSS compared to the control and DSS 
only groups (***, **, * p < 0.0001). Additionally, the average OD value of Map + DSS 
IgG2a is significantly lower compared to Map only IgG2a (*, p = 0.0005). Data are presented 
as pooled group means ± standard errors of the mean derived from one of two experiments. 
 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
Control DSS only Map only Map + DSS Control DSS only Map only Map + DSS
IgG1 IgG2a
A
vg
 O
D ***
*
**
122 
 
 
Fig. 7.  Change in body weight in SCID mice inoculated with saline (Control); infected with 
Map only (Map only); inoculated with saline and treated with DSS (DSS only); and mice 
infected with Map and treated with DSS (Map + DSS). Map + DSS mice lost a statistically 
significant amount of body weight relative to all other treatment groups (*, p < 0.03) at day 6 
and at day 5 (*, p < 0.05) compared to the control and DSS only groups.  DSS only mice lost 
more weight relative to the control at day 5 (**, p < 0.04). Data are represented as the mean ± 
standard error of the means from two separate experiments including 6 Map + DSS mice, 4 
Map only, 4 DSS only mice and 4 control mice.  
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Fig. 8 Cecal lengths in SCID mice inoculated with saline (Control); infected with Map only 
(Map only); inoculated with saline and treated with DSS (DSS only); and mice infected with 
Map and treated with DSS (Map + DSS). The average cecal length in Map + DSS mice was 
shorter relative to all other treatment groups (*, p < 0.001).  Data are represented as the mean 
± standard error of the means from two separate experiments including 6 Map + DSS mice, 4 
Map only, 4 DSS only mice and 4 control mice.  
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Fig. 9  Cecal histologic lesion scores in SCID mice inoculated with saline (Control); infected 
with Map only (Map only); inoculated with saline and treated with DSS (DSS only); and 
mice infected with Map and treated with DSS (Map + DSS). Cecal lesion scores were 
significantly higher in Map + DSS mice relative to all other treatment groups (**, p 
<0.0001).  Additionally, DSS only mice had higher lesion scores relative to the control (*, p 
= 0.02). Data are represented as the mean ± standard error of the means from two separate 
experiments including 6 Map + DSS mice, 4 Map only, 4 DSS only mice and 4 control mice.  
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Fig.10. Log colony forming units per gram of tissue in SCID mice inoculated with saline 
(Control); infected with Map only (Map only); inoculated with saline and treated with DSS 
(DSS only); and mice infected with Map and treated with DSS (Map + DSS). There were no 
significant differences between any of the tissues in any of the treatment groups. Data are 
represented as the mean ± standard error of the means from two separate experiments 
including 6 Map + DSS mice and 4 Map only mice. TNTC = too numerous to count. 
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Fig. 11 Cecal cytokine mRNA expression in SCID mice inoculated with saline (Control); 
infected with Map only (Map only); inoculated with saline and treated with DSS (DSS only); 
and mice infected with Map and treated with DSS (Map + DSS). IL-1β and TNF-α mRNA 
expression was significantly increased in Map + DSS treated mice relative to all other 
treatment groups (*, p < 0.0009 and ** p < 0.0062). Data are represented as the mean ± 
standard error of the means from one of two separate experiments, including 3 Map + DSS 
mice, 2 Map only, 2 DSS only mice and 2 control mice. β-actin was used as an internal 
control, with target gene mRNA expression being normalized to β-actin mRNA within the 
same tissue.  
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Fig. 12   Cecal caspase-1 mRNA expression in BALB/c and SCID mice inoculated with 
saline (Control); infected with Map only (Map only); inoculated with saline and treated with 
DSS (DSS only); and mice infected with Map and treated with DSS (Map + DSS). For 
BALB/c mice, caspase-1 was significantly increased in Map + DSS treated mice relative to 
all other treatment groups (**, p < 0.0001). For SCID mice, Caspase-1 was significantly 
increased in DSS only treated mice relative to all other treatment groups (*, p < 0.0004). For 
BALB/c mice, data are represented as the mean ± standard error of the means from one of 
two separate experiments, including 7 Map + DSS mice, 2 Map only, 5 DSS only mice and 2 
control mice. β-actin was used as an internal control, with target gene mRNA expression 
being normalized to β-actin mRNA within the same tissue.  
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Abstract 
The function of intestinal macrophages is modulated and defined by its local environment. 
Therefore, it is essential to understand if exposure to an intracellular pathogen can cause a 
shift in macrophage phenotype. We have previously demonstrated that persistent enteric 
Mycobacterium avium subsp. paratuberculosis (Map) infection in SCID mice exacerbates 
dextran sulfate sodium (DSS) mediated intestinal inflammation. Enhanced disease is 
associated with increased expression of IL-1β, suggesting macrophages are an important 
effector cell in our model. Our primary aim was to define the IL-1β expression profiles in 
Map infected macrophages. To accomplish this, we analyzed both in vivo and in vitro IL-1β 
protein expression in Map infected macrophages. Additional aims included evaluating the 
functional phenotype, the total number of F4/80+ cells and inflammasome mediated IL-1β 
production in Map infected macrophages. By immunohistochemistry, Map-infected 
macrophages had similar expression of pro-IL-1β that was not affected by DSS treatment. 
However, macrophages infected with Map and exposed in vitro to LPS had augmented IL-1β 
production which was not dependent on the NALP3 inflammasome. Map antigen positive 
cells from Map infected and DSS treated mice also had increased iNOS expression and 
greater numbers of F4/80+ cells. In conclusion, these observations indicate that Map 
infection sensitizes macrophages to a pro-inflammatory phenotype defined by increased IL-
1β and iNOS expression following injury to the intestinal mucosa.  
 
Key words: Macrophage, IL-1β, inflammasome, Mycobacterium avium subsp. 
paratuberculosis, iNOS  
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Introduction  
Excessive activation of the innate immune system is thought to play an important role 
in the pathogenesis of the inflammatory bowel diseases (IBD). This is highlighted by the 
success of anti-TNF-α therapy in the treatment of Crohn’s disease (CD).[1] Moreover, other 
cytokines of the innate immune system, such as IL-1β, also appear to have an important role, 
as evidenced by enhanced secretion of Il-1β by mononuclear cells isolated from the inflamed 
mucosa from patients with Crohn’s disease.[2] Even though it has been shown that intestinal 
macrophages play a protective role in an experimental model of colitis, these cells represent 
potential sources of these pro-inflammatory cytokines; therefore, it is critical to tightly 
regulate their function to prevent unwanted injurious inflammation and emphasizes the need 
to understand the triggers that may cause a shift in their phenotype to promote 
inflammation.[3] 
Although the evidence indicates that pro-inflammatory cytokines are involved in the 
evolution of the intestinal inflammation in IBD, it is not clear how an infection with an 
opportunistic pathogen that targets macrophages impact mucosal macrophage function. This 
is important considering the continuous exposure of the intestine to opportunistic pathogens 
and predisposition of certain populations to enteric infections.  Mycobacterium avium ss. 
paratuberculosis (Map) has a tropism for intestinal macrophages and historically has been 
incriminated as having a role in CD. Mounting evidence indicates that Map is not the primary 
etiology of CD .[4]  However, recent studies have suggested that Map may act as an immune 
modulator in susceptible individuals thereby promoting mucosal inflammation initiated by 
other causes. [5] In support of this hypothesis, oral exposure to Map, without intestinal 
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colonization, is capable of augmenting intestinal inflammation in IL-10 deficient mice.[6] 
These authors demonstrated enhanced T-cell immunoreactivity to a conserved mycobacterial 
antigen (Ag85), suggesting that exposure to various non-tuberculous mycobacterial (NTM) 
species have the potential to influence intestinal inflammation. This is relevant because 
environmental exposure is reported and underscores the need to understand how exposure to 
such intracellular pathogens may modulate the phenotype of intestinal macrophages.[7]  
We have previously reported that subclinical and persistent enteric Map infection 
sensitizes mice to exacerbation of DSS mediated intestinal inflammation. Exacerbation of 
disease in our model is associated with enhanced activation of the innate immune response; 
which includes high IL-1β expression. In the current study we set out to understand how Map 
infection influences intestinal mucosal macrophage phenotype and function in an 
environment of epithelial injury. We analyzed both in vivo and in vitro IL-1β protein 
expression in Map infected macrophages. In cultured macrophages we explored cellular 
pathways culminating in inflammasome activation and IL-1β secretion. The inflammasome is 
essential for caspase-1 activation which, in turn, is necessary for processing of pro-IL-1β into 
mature IL-1β.[22] To accomplish this aim, we infected mouse macrophages that were 
deficient in different components of the inflammasome. Based on the in vitro ability of Map 
to prime macrophages for enhanced TNF-α expression following exposure to LPS, we 
hypothesized that Map infection would prime macrophages for increased expression of IL-
1β, with its secretion requiring a second signal, such as exposure to commensal bacteria.[8] 
To evaluate the functional phenotype of Map infected macrophages, we examined the 
expression of inducible nitric oxide synthase (iNOS), a marker associated with classic 
132 
 
macrophage activation and enhanced killing of intracellular pathogens; and arginase, an 
enzyme characteristic of alternatively activated as well as wound-healing macrophages.[9, 
10] We hypothesized that there would be minimal iNOS expression relative to arginase 
which would be expected to be increased since Map infected macrophages do not 
characteristically express iNOS and because SCID macrophages are prone to express 
arginase.[11-13] Our results demonstrate that macrophages in our in vitro and in vivo Map 
infection models have a pro-inflammatory profile defined by the enhanced production and 
secretion of IL-1β and increased expression of iNOS.  
Materials and methods 
Animals  
Conventionally reared 6-8 week-old male C.B-17 scid (SCID) mice were purchased 
from The Jackson Laboratory (Bar Harbor, ME), weighed approximately 22-24 grams, and 
were housed in micro-isolation units that were individually ventilated in a positive pressure 
Thoren unit caging system at the Iowa State University College of Veterinary Medicine 
biosafety level II animal care facility. All animal experiments were approved by the 
Institutional Animal Care and Use Committee of Iowa State University. 
Experimental design  
Tissues from SCID mice utilized in this study were part of a previously reported 
study.  In brief, two separate experiments were performed with 4 and 5 mice per Map 
infected and saline treatment group, respectively.  In each experiment, mice were assigned to 
one of two study groups and either given a single intraperitoneal sham injection of saline or 
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Map. Following inoculation, body weights of the mice were measured at weekly intervals 
and feces were periodically collected for isolation of Map. At approximately 3 months post-
inoculation, acute intestinal injury was chemically induced by administering a suboptimal 
concentration of 2% dextran sulfate sodium (DSS; MP Biomedicals, Solon, OH) in the 
drinking water for 6 days. We established this dose by determining the lowest DSS 
concentration in the drinking water that would induce minimal but perceptible microscopic 
lesions in the cecal and colonic mucosa. While the mice were administered DSS, they were 
weighed daily and on day 6 all of the mice were euthanized with CO2 inhalation and 
necropsies were performed.   
Bacterial Inoculum and Infection 
The Map strain K10 was a clinical isolated obtained from the National Animal 
Disease Center (Ames, IA) and maintained at 37°C in Middlebrook 7H9 broth supplemented 
with mycobactin J. Logarithmic growth-phase bacteria were washed and resuspended in 
sterile saline for inoculation. Bacterial concentration was determined by measuring at 540 
nm, comparing the absorbance optical density to the standard curve and adjusted to a final 
concentration of 1x108 colony-forming units. Controls were given a sham inoculation of 
saline. The Map inoculum used in these studies was shown to have greater than 90% viability 
via fluorescein diacetate staining and flow cytometry analysis prior to inoculation. In 
addition, challenge inocula were confirmed negative for contaminants by streaking onto 
sheep blood agar plates 24 h prior to inoculation.  
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Immunohistochemistry 
IL-1β, iNOS, and arginase/Map combined and F4/80 only staining  
Before staining, slides were deparaffinized, rehydrated, and processed for 
immunohistochemistry (IHC). Antigen retrieval was accomplished by microwaving slides in 
a pH 10 buffer for 5 minutes for iNOS; 0.1% triton X-100 in PBS for 20 minutes at RT for 
IL-1β; microwaving in pH 6 citrate buffer for 5 minutes for arginase; and 2% protease in Tris 
buffer for 20 minutes at RT for F4/80. Slides were then blocked with 10% normal goat serum 
at room temperature. Primary antibodies were used at the following dilutions and incubated 
overnight at 4°C: F4/80 at 1:1,000 (eBioscience, San Diego, CA); arginase at 1:6,000 
(Fitzgerald Industries; Concord, MA); IL-1β at 1:500 (Santa Cruz Biotechnology, Inc; Santa 
Cruz, CA);  and iNOS at 1:1,500 (Upstate, Billerica, MA). Biotinylated goat anti-rabbit IgG 
at 1:400 or goat anti-rat IgG F(ab’)2 fragment secondary antibodies at1:250 were added and 
incubated at room temperature for 30 minutes. HRP-streptavidin diluted 1:200 was added to 
the slides for 15 minutes. DAB was added to the slides until optimal staining developed (10-
15 minutes). Following staining for iNOS, arginase, and IL-1β, Map antigen staining was 
performed. To accomplish this, we used a polyclonal rabbit anti–M. bovis antibody that has 
extensive cross-reactivity with Map and is a useful tool for the identification of Map.[14]  
Rabbit anti–M. bovis (Dako Cytomation, Carpinteria, CA) was added at 1: 4,000 for 30 
minutes at RT. Alkaline phosphatase–streptavidin diluted 1:200 was added to the slides for 
15 minutes. Vector Red Substrate was then added until optimal staining developed (8-10 
minutes). 
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Evaluation of stained slides 
We restricted our analysis to ceca from SCID mice so that a sufficient number of Map 
antigen positive macrophages could be evaluated. The number of ceca evaluated included 
samples from 3 controls, 3 DSS only, 3 Map only infected, and 3 to 4 Map infected and DSS 
treated mice. A previously described method was used for evaluation of IL-1β, arginase, and 
iNOS immunoreactivity and was adapted for use in this study.[11, 15] All Map antigen 
positive 40x fields of the cecum were scored for the frequency and intensity of 
immunoreactivity for IL-1β, arginase, and iNOS in Map infected mice. For DSS only and 
control mice at least 10 40x random fields were evaluated for iNOS and IL-1β 
immunoreactivity.  Because arginase expression was randomly scattered throughout the 
entire lamina propria of the cecum in all treatment groups, arginase immunoreactivity in DSS 
only and control mice was restricted to focal collections of mononuclear cells. The 
distribution of cell staining was scored on a scale of 0–3 (0 = 0%, 1 = < 25%, 2 = 25–75%, 
and 3 > 75% immunoreactive cells). The intensity of the cell staining was also scored on a 
scale from 0–3 (0 = no staining, 1 = mild intensity, 2 = moderate intensity, and 3 = intense).  
There was a maximum score of 6 per 40x field evaluated. For evaluation of F4/80 
immunoreactivity, all positive F4/80 cells within the cecum were counted for each animal.  
Bone-marrow derived macrophages (BMDM) and infection with Map 
Femurs and tibias from NALP3-, ASC-, and caspase-1- deficient mice were kindly 
provided by Dr. Sutterwala (University of Iowa, Carver College of Medicine). The 
generation of NALP3-, ASC-, and caspase-1- deficient mice has been described.[16-18] 
Caspase-1 deficient mice were backcrossed onto the C57BL/6 genetic background for 10 
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generations. ASC- and NALP3-deficient mice were backcrossed onto the C57BL/6 genetic 
background for nine generations. Age and sex-matched C57BL/6 mice purchased were used 
as WT controls. Bone marrow cells were obtained by flushing the femurs and tibias from 
mice with complete tissue culture medium (CTCM) on ice. Complete tissue culture medium 
was prepared by adding 10% fetal bovine serum, 0.05 mM 2-mercaptoethanol, penicillin G 
(100U/ml), streptomycin (100 µg/ml), 2 mM L-glutamine, and 25mM Hepes to DMEM. 
Viability of cells was assessed by trypan blue exclusion and total cells were adjusted to 
approximately 15-20 x 106 cells and plated in 150x15 mm petri dishes with L929 conditioned 
medium containing DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 
1 mM sodium pyruvate, and 0.1 mM non-essential amino acid mix and maintained at 37°C, 
5% CO2 in a humidified incubator. At day 2 the supernatants of bone marrow cells were 
supplemented with additional L929 conditioned medium. At day 6, medium was removed 
from the petri dish and replaced by ice cold PBS, incubated on ice for 20 minutes, and 
macrophages were detached using a cell scraper.  BMDM were pelleted, resuspended in 
CTCM and 5 x 105 cells/well were plated in 24 well plates. The next day, medium was 
replaced with CTCM without penicillin/streptomycin and cells were infected with Map with 
a final multiplicity of infection of 10:1. Cells were then incubated for 4 hours, washed with 
PBS and then stimulated with LPS at 1µg/ml in CTCM without penicillin and streptomycin. 
Supernatants were subsequently harvested at 24 and 48 hours and frozen at -70°C until 
analyzed for IL-1β.  
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IL-1β ELISA  
A commercially available ELISA kit (eBioscience, San Diego, CA) was used for the 
detection of IL-1β protein in cell culture supernatants. The appropriate recombinant cytokine 
protein was used as a positive control to generate the standard curve.  The detection limit was 
8 pg/ml. Results are expressed as the mean (± SEM) pg/ml. 
Statistical analysis 
For all parameters, treatment group means were compared first with an overall F-test 
and then followed by post-hoc Student’s t-test with group mean differences considered 
significant if the p-value was <0.05. Data are presented as the mean value ± standard error of 
the mean except where stated otherwise.  
Results 
Intestinal F4/80 immunoreactivity in mice with persistent mycobacterial infection    
 Macrophages are a prominent component of the inflammatory infiltrate in SCID mice 
treated with DSS and are a target cell of the intracellular pathogen Map.[19, 20] 
Consequently, we wanted to assess the relative number of macrophages within the intestinal 
mucosa of mice exposed to DSS and persistently infected with Map. To achieve this, we 
performed immunohistochemistry with the macrophage specific F4/80 antibody.[21] Map + 
DSS mice had a greater number of F4/80 positive cells per 40x field examined relative to all 
other treatment groups (Fig.1, **, p < 0.0001). Also, DSS only mice had greater numbers of 
F4/80 positive cells compared to Control and Map only mice (*, p < 0.0009). Individual 
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F4/80 positive cells were primarily present in the edematous submucosa subjacent to lesions 
in the overlying mucosa or surrounding cecal crypts (Fig. 6, A).  
IL-1β protein expression and secretion from Map infected macrophages 
We have previously reported that IL-1β mRNA is increased in the cecal mucosa of 
SCID mice infected with Map and given DSS; therefore, one of our goals was to determine if 
there were differences in IL-1β immunoreactivity between the different treatment groups of 
mice, focusing where applicable on Map infected macrophages. To accomplish this we used 
a dual immunohistochemical staining method to label IL-1β and Map antigens. In cecal 
sections, cytoplasmic Map antigen was abundant and confined to cells with macrophage type 
morphology.  In Map infected mice we evaluated dual labeling cells (Map + IL-1β) and in 
non-infected mice we evaluated all macrophages. The IL-1β antibody used in this study was 
specific for pro-IL-1β. In Map infected mice, pro-IL-1β immunoreactivity was restricted to 
the cytoplasm of Map antigen positive cells. Pro-IL-1β and Map antigen immunoreactivity 
was not observed in macrophages from any of the DSS only or control mice. We observed 
similar levels of pro-IL-1β in both Map only and Map + DSS mice (Fig. 2). However, pro-
IL-1β immunoreactivity for both Map + DSS (Fig. 2, **, p < 0.0001) and Map only (Fig. 2, 
*, p = 0.0002) mice was higher relative to the control and DSS only groups. Representative 
pro-IL-1β immunoreactivity is shown in Figure 6 (B).  
The observation of similar pro-IL-1β immunoreactivity between Map only and Map + 
DSS mice suggested that Map infection may prime macrophages for enhanced IL-1β 
production. We hypothesized that disruption of the mucosal barrier by DSS and exposure to 
normal floral antigens, such as LPS, would serve as the trigger for secretion of mature IL-1β. 
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To address this hypothesis, we utilized an in vitro model system where we infected C57BL6 
mouse macrophages (WT) with Map and subsequently exposed them to E. coli LPS. Map 
infected and LPS exposed macrophages had augmented IL-1β production relative to all other 
treatment groups (Fig. 3, *) at 24 and 48 hours post-infection. Although smaller in magnitude 
compared to Map infected and LPS exposed macrophages, Map infection and LPS exposure 
alone also resulted in IL-1β production. 
We next set out to define pathways of IL-1β secretion using macrophages from 
C57BL6 mice deficient in components of the inflammasome pathways. The inflammasome is 
essential for caspase-1 activation which, in turn, is necessary for processing of pro-IL-1β into 
mature IL-1β.[22] The inflammasome is a dynamic molecular entity and is composed of 
different components to achieve activation of caspase-1 depending on the inciting stimuli. 
The NALP3 inflammasome is associated with caspase-1 activation following infection with 
Mycobacterium tuberculosis; therefore, we used mouse macrophages deficient in NALP3 
and an adaptor protein associated with this complex, ASC, to determine if this pathway was 
sufficient for IL-1β production following infection with Map.[23] Mouse macrophages 
deficient in NALP3 and infected with Map and/or exposed to LPS were still capable of 
producing IL-1β. However, deficiency of the adaptor protein ASC resulted in a marked 
reduction in IL-1β, with minimal production at 48 hours in Map infected and LPS exposed 
macrophages. Similarly, there was a marked reduction in IL-1β in  caspase-1 deficient 
macrophages, yet at 48 hours there was capase-1 independent production of IL-1β in Map 
infected and LPS exposed macrophages.       
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Functional phenotype of Map infected intestinal macrophages  
We performed immunohistochemistry for arginase, a marker of wound-healing and 
alternative activated macrophages, and iNOS, a marker associated with classic macrophage 
activation and enhanced killing of intracellular pathogens, to define the functional phenotype 
of Map infected intestinal macrophages.[9, 24] We used a dual label for Map/arginase and 
focused on Map infected macrophages as described for IL-1β detection.  We focused on co-
localized Map with iNOS or arginase antigen positive cells in Map infected mice. Positive 
iNOS immunoreactivity in DSS only mice was confined to the cytoplasm of apical 
enterocytes associated with areas of mucosal ulceration and erosion. For Map infected mice 
cytoplasmic iNOS positive staining was confined to Map infected cells.  iNOS 
immunoreactivity was not observed in control mice. Map + DSS infected mice had a higher 
iNOS score relative to all other treatment groups (Fig.4, **, p < 0.002). Map only mice had 
higher iNOS immunoreactivity scores compared to DSS only and control mice (*, p < 0.002). 
In Map infected mice, iNOS immunoreactivity was not observed in non-infected 
macrophages.  
There was diffuse and randomly scattered cytoplasmic arginase immunoreactivity 
throughout the lamina propria of the intestinal mucosa in mice of all treatment groups. 
Labeling occurred within Map infected and non-infected macrophages. In Map infected 
mice, evaluation of arginase immunoreactivity was confined to Map antigen positive foci. 
Assessment of arginase immunoreactivity in DSS only and control mice was limited to well 
defined aggregates of mononuclear cells, with morphology similar to gut associated 
lymphoid tissue of conventional mice. In Map infected mice, there was no difference in 
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arginase immunoreactivity in Map infected or non-infected macrophages and the graph 
depicts scoring for Map infected cells only (Fig. 5). Map infection did not affect arginase 
immunoreactivity relative to control mice. There was a trend for decreased arginase 
immunoreactivity in DSS only mice but this did not reach statistical significance. 
Representative arginase and iNOS staining is shown in Figure 6 (C, D, respectively). 
Discussion 
We set out to understand how subclinical Map infection in the context of acute 
mucosal injury potentiates innate immune responses. We accomplished this by evaluating the 
functional phenotype and expression of IL-1β in Map infected macrophages and by 
examining the relative number of macrophages in Map enhanced intestinal lesions. This is 
relevant because Map has been suggested to act as an immune modulator, but not as a 
primary pathogen, in CD.[5] With support from our in vitro studies, our results suggest that  
Map infected macrophages in our in vivo model have a pro-inflammatory profile defined by 
the enhanced expression  of IL-1β and iNOS, which corresponds with an increase in the 
number of lamina propria macrophages. Combined with the observation that DSS treatment 
did not affect the expression of pro-IL-1β in Map infected mice, our results indicate that Map 
infection promotes a shift towards classic macrophage activation, which is sustained and 
potentially amplified following interaction with a second stimulus, namely, LPS. Moreover, 
it appears that Map infection primes the uninjured mucosa for augmented macrophage 
recruitment following an intestinal insult.   
Intestinal macrophages are dynamic effector cells which play a critical role in 
maintaining mucosal homeostasis.[25] Map represents an appropriate model organism for 
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opportunistic infections that can be used to better understand how subclinical infections alter 
intestinal macrophage phenotype and whether these changes translate to increased 
susceptibility to intestinal injury. Limited numbers of studies have specifically addressed 
how subclinical infections of intestinal macrophages affect inflammation in a model of 
intestinal injury. Cytomegalovirus (CMV), a virus known to infect intestinal macrophages, is 
one of the few pathogens that has been studied in a model of experimental colitis.[26] 
Onyeagocha et al. have shown that latent CMV infection sensitizes mice to exacerbation of 
disease following DSS mediated intestinal injury.[27]  It was proposed that increased clinical 
disease was due to CMV mediated increases in gut permeability that promoted an enhanced 
innate immune response following disruption of the intestinal mucosa by DSS. Although 
CMV is capable of infecting intestinal macrophages, it has a relatively broad cellular 
tropism, for example, it is able to infect epithelial and endothelial cells.[28] In contrast, Map 
replication is primarily restricted to macrophages, thereby providing a model to specifically 
explore how infection of intestinal macrophages alters intestinal homeostasis.[19]   
The findings of the current study are unique in that we have demonstrated that 
subclinical Map infection of intestinal macrophages is capable of sensitizing the intestinal 
mucosa for an enhanced innate immune response following acute mucosal injury.  This is 
based on the observation that Map infection in the uninjured intestine can promote the 
expression of iNOS, in conjunction with our in vitro observation that Map infection 
augments IL-1β following exposure to LPS.   In the current study we observed similar levels 
of pro-IL-1β in Map infected mice with and without DSS administration. This suggests that 
Map infection promotes increased synthesis of pro-IL-1β and storage in the cytoplasm. We 
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hypothesized that LPS prompts full inflammasome activation and secretion of IL-1β. To 
examine this possibility, we infected macrophages in vitro with Map then exposed them to 
LPS to mimic translocation of commensals across a damaged mucosal barrier. We observed 
significant increases in IL-1β secretion into the culture supernatants from macrophages that 
were infected with Map and exposed to LPS. Even though previous studies and the current 
study demonstrate that Map infection alone is sufficient for IL-1β production, our results 
support the hypothesis that both production of mature IL-1β and its secretion is enhanced by 
the combination of Map and LPS.[29, 30] Support for our observation of LPS enhanced 
expression of IL-1β by Map infected macrophages is provided by a study in which LPS was 
shown to enhance TNF-α expression by Map infected macrophages.[8] However, the precise 
mechanism associated with Map enhanced IL-1β expression remains to be defined. Map 
infection may have primed macrophages for enhanced production of IL-1β by promoting a 
basal level of IL-1β expression, with LPS serving as the trigger for its enhanced activation 
and secretion. Piccini et al have recently reported that various microbial components, 
including LPS, are competent to induce both the processing and secretion of IL-1β.[31] This 
mechanism was proposed to be mediated by extracellular release of endogenous ATP from 
monocytes. Following ATP release there is autocrine stimulation of the P2X7 receptor, 
causing K+ efflux and phospholipase A2 activation, both of which are necessary for the 
processing and secretion of IL-1β.  
Since Map infection alone is capable of eliciting IL-1β production, we wanted to try 
and identify how Map induces its production. Formation of mature IL-1β requires processing 
mediated by caspase-1 whose activation, in turn, requires assembly and activation of a 
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multiprotein complex called the inflammasome.[22, 32]  Originally, the inflammasome was 
structurally defined by apoptosis-associated speck-like protein containing a CARD (ASC), 
NACHT- LRR- and pyrin domain-containing protein 1 (NALP), caspase-5 and caspase-
1.[33] A more recently described inflammasome brings together two caspase-1 molecules 
and is composed of NALP-3 (cryoporin) and two adapter proteins cardinal (CARD8) and 
ASC.[34] We chose to evaluate the NALP3 inflammasome because it is activated by 
Mtb.[23] Macrophages deficient in the NALP3 inflammasome were still capable of 
producing IL-1β indicating that an alternative inflammasome platform is involved for Map 
mediated IL-1β production. However, the ASC component of the NALP3 inflammasome is 
necessary because there was minimal production of IL-1β in macrophages lacking this 
protein, thus suggesting that an ASC associated inflammasome is important, such as NALP1 
or NALP2.[33, 35] The ability of Map infected and LPS stimulated macrophages to produce 
IL-1β in the absence of caspase-1 was unexpected. However, caspase-1 independent 
production of IL-1β has been described. One mechanism involves matrix metalloproteinases 
(MMP), which can be induced by both LPS and Map stimulated macrophages.[36, 37] 
Moreover, caspase-1 independent production of IL-1β has been described in a mouse model 
of Mtb infection.[38]    
Free radical injury of the intestinal mucosa is thought to play a role in IBD as 
indicated by increases in nitric oxide and iNOS in patients with IBD and based on the 
amelioration of DSS mediated colitis following decreases in nitric oxide.[39, 40] Map 
infected macrophages had an augmented activated phenotype following injury to the 
intestinal mucosa characterized by an increase in the expression of iNOS. We hypothesized 
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that there would be minimal expression of iNOS. Map infected bovine macrophages do not 
characteristically express iNOS in vitro and in vivo; however, its expression has been 
demonstrated in peripheral blood mononuclear cells of subclinically cattle and in hepatic foci 
of granulomatous inflammation in Map infected athymic nude mice.[11, 13, 41],[42] This 
increase may have been due to superimposed exposure to intestinal antigens, such as LPS, 
following injury to the mucosal barrier.[43] Augmented iNOS levels may also be partially 
explained by the increases in IL-1β we observed since it is capable of increasing iNOS 
expression.[44]Map infection did not affect arginase expression, a marker of wound healing 
macrophages.[9] To the authors’ knowledge, there are no other reports on arginase 
expression in Map infected macrophages. There may be reciprocal regulation of iNOS and 
arginase in Map infected cells. The increase in iNOS expression may have caused a decrease 
in arginase expression, since both enzymes compete for the same substrate, L-arginine.[45] 
In contrast to the Map infected mice, there was a trend for decreased arginase expression in 
DSS only mice in which arginase would have been expected to be increased because it has 
been demonstrated that exposure to LPS increases arginase expression in SCID 
macrophages.[12]  
Higher doses of DSS induce colitis in SCID mice, and macrophages likely play an 
important role in this model.[46, 47] Our observation of increased expression of both a 
macrophage associated cytokine, IL-1β, and iNOS following infection with an intracellular 
pathogen of macrophages suggests that this cell type is an important effector cell in our 
model. We observed increased numbers of F4/80 positive cells, a marker of mouse 
macrophages, in SCID mice treated with DSS, with the greatest numbers being observed in 
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Map + DSS treated mice. The increase in F4/80 positive cells was primarily restricted to the 
edematous submucosa and cecal crypts and did not appear to be associated with foci of Map 
localization. A previous study with a different macrophage marker has demonstrated that 
macrophages predominate in the SCID DSS model relative to neutrophils.[20] Although we 
did not evaluate chemokine levels, their expression was likely elevated in foci of 
inflammation. By analogy, TNF-α mediated macrophage production of chemokines is an 
important mechanism for macrophage recruitment in mouse models of Mtb.[48, 49] 
Previously, we have documented increased TNF-α expression in Map infected and DSS 
treated SCID mice. Our results imply that subclinical Map infection potentiates the active 
recruitment of macrophages to sites of intestinal injury.  
Collectively, our observations from this study suggest that Map infection causes a 
shift in intestinal macrophage effector function which results in enhanced pro-inflammatory 
properties defined by increased secretion of IL-1β following exposure to LPS and increased 
expression of iNOS. This builds on and characterizes a possible mechanism associated with 
our previous studies where we have shown that Map infection is associated with enhanced 
innate immune activation in a model of enhanced intestinal injury. Furthermore, our studies 
indicate that Map induced production of IL-1β is not dependent on the NALP3 
inflammasome, and may involve a caspase independent mechanism, but not in Map infected 
and LPS treated macrophages. We believe this model represents an important tool that can be 
used to advance our understanding of how subclinical infection of macrophages alters their 
homeostatic promoting anti-inflammatory profile. 
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Fig. 1 Average number of F4/80+ cells per 40x field in the ceca from mice inoculated with 
saline (Control); infected with Map only (Map only); inoculated with saline and treated with 
DSS (DSS only); and mice infected with Map and treated with DSS (Map + DSS). The 
number F4/80+ cells was significantly higher in Map + DSS relative to all other treatment 
groups (**, p < 0.0001). Also, the number of F4/80+ cells was greater in DSS only mice 
compared to Map only and Control mice (*, p < 0.0009). Data are represented as the mean ± 
standard error of the means from two separate experiments including 4 Map + DSS mice, 3 
Map only, 3 DSS only mice and 3 control mice.  
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Fig. 2 Average pro-IL-1β immunoreactivity score per 40 x field in the ceca from mice 
inoculated with saline (Control); infected with Map only (Map only); inoculated with saline 
and treated with DSS (DSS only); and mice infected with Map and treated with DSS (Map + 
DSS). The average pro-IL-1β reactivity was not different between Map only and Map + DSS 
mice. The average pro-Il-1β immunoreactivity score for both Map only (*, p = 0.0002) and 
Map + DSS (*, p < 0.0001) mice was higher compared to DSS only and control mice. Data 
are represented as the mean ± standard error of the means from two separate experiments 
including 3 Map + DSS mice, 3 Map only, 3 DSS only mice and 3 control mice. 
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Fig.3 Average IL-1β production in C57BL6 Asc -/-, Nalp3 -/-, Caspase 1 -/- deficient and 
wild-type (WT) macrophages infected with Map for 4 hours and subsequently exposed to 
LPS at 1µg/ml. In wild-type macrophages, Map infected and LPS exposed macrophages had 
the greatest amount of IL-1β production. Deficiency of Asc, Capsase-1, or Nalp3 did not 
affect Map infected and LPS exposed macrophage secretion of IL-1β; however, Map only 
and LPS only mediated production of IL-1β was affected by the absence of Asc and Caspase-
1. Cell culture supernatants were collected at 24 and 48 hours and measured for IL-1β 
production by ELISA. Duplicate wells were assayed and results are expressed as the mean ± 
standard error of the means and are representative of one experiment.   
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Fig. 4 Average iNOS immunoreactivity score per 40x field in the ceca from mice inoculated 
with saline (Control); infected with Map only (Map only); inoculated with saline and treated 
with DSS (DSS only); and mice infected with Map and treated with DSS (Map + DSS).  
iNOS immunoreactivity was only observed in macrophages infected with Map. The average 
iNOS immunoreactivity was significantly higher in Map + DSS mice compared to all other 
treatment groups (**, p < 0.002). The average iNOS immunoreactivity score for Map only 
mice was higher compared to DSS only and control mice (*, p-value < 0.002). Data are 
represented as the mean ± standard error of the means from two separate experiments 
including 3 Map + DSS mice, 3 Map only, 3 DSS only mice and 3 control mice.  
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Fig. 5 Average arginase immunoreactivity score per 40x field in the ceca from mice 
inoculated with saline (Control); infected with Map only (Map only); inoculated with saline 
and treated with DSS (DSS only); and mice infected with Map and treated with DSS (Map + 
DSS). The average arginase immunoreactivity was not different between any of the treatment 
groups. Data are represented as the mean ± standard error of the means from two separate 
experiments including 3 Map + DSS mice, 3 Map only, 3 DSS only mice and 3 control mice.  
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Fig. 6 Representative photomicrographs from mice infected with Map and treated with DSS 
demonstrating F4/80 (A), Map and pro-IL-1β (B), arginase (C), and iNOS immunoreactivity 
(D) in the ceca of SCID mice infected with Map and treated with DSS. F4/80 
immunoreactivity was primarily confined to the submucosa and cecal crypts. 
Immunoreactivity for Map, F4/80, pro-IL-1β, arginase, and iNOS was present within the 
cytoplasm of cells with macrophage type morphology. F4/80, pro-IL-1β, arginase, and iNOS 
stains are brown, whereas the Map stain is red. Bar = 50 µm.  
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General Conclusions 
 
Our central hypothesis for this thesis was that persistent intestinal mycobacterial 
infection sensitizes the host to acute intestinal injury. Mycobacterium avium subsp. 
paratuberculosis is an appropriate model organism to address this hypothesis since it can 
establish subclinical intestinal infection in the mouse and because of its tropism for 
macrophages. This allows for the evaluation of the relationship between pathogen-induced 
alterations in macrophage effector function and its consequences on intestinal 
homeostasis.[1, 2] Other in vivo models examining the interaction between chronic infection 
and mucosal injury are few. The best example is provided by a single study conducted with 
cytomegalovirus (CMV).[3, 4]  In this study subclinical CMV infection exacerbated 
subsequent DSS mediated intestinal inflammation. However, unlike Map, the cellular 
tropism of CMV is broad and not restricted to macrophages.[5] It is relevant to use Map in 
our model because it has been proposed to act as an immunomodulator in Crohn’s disease 
and because intestinal macrophages are consistently exposed to low level pathogens such as 
non-tuberculous mycobacteria.[6, 7]  Collectively, the results we have generated from this 
thesis support the central hypothesis and suggest that persistent enteric mycobacterial 
infection can prime the intestinal mucosa for an excessive innate immune response following 
acute mucosal injury.   
Persistent enteric mycobacterial infection enhances sensitivity to acute mucosal injury  
In Chapter 2 our primary goal was to determine if chronic intestinal Map infection 
would influence subsequent DSS mediated intestinal inflammation. We hypothesized that 
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exposure to Map would sensitize the host to acute mucosal injury. To address this goal, we 
utilized a mouse model of intestinal Map infection.[2, 8] BALB/c mice were infected with 
Map for 90 days followed by a low dose of DSS in the drinking water to induce mild 
intestinal injury. In these mice, we evaluated clinical signs of disease, such as changes in 
body weight and frequency of rectal blood, and assessed gross and histologic cecal lesions. 
Our results support the hypothesis that subclinical and chronic intestinal mycobacterial 
infection amplifies acute mucosal injury. This was demonstrated by increased weight loss, 
increased frequency of rectal blood, and exacerbation of gross and histologic cecal lesions in 
mice infected with Map and treated with DSS. An additional observation was decreased Map 
burden in the small intestines of DSS treated mice, and we hypothesize that this was related 
to macrophage activation following DSS treatment. Based on  demonstration of viable Map 
and acid- fast bacilli in the lymphoid tissue of the cecal tonsil, a tissue that plays a central 
role in the development of DSS-mediated intestinal inflammation, in conjunction with the 
fact that Map is an intracellular pathogen of macrophages, our results support a hypothesis  
that excessive activation or dysregulation of the mucosal immune system was responsible for 
the enhanced disease in our model.[9]     
Immune responses associated with intestinal mucosal injury in mice subclinically    
 infected with Mycobacterium avium subsp. paratuberculosis 
In Chapter 3 we set out, to define the intestinal and systemic immune responses that 
were associated with sensitivity of Map-infected mice to DSS in our model. We hypothesized 
that an additive Th1 immune response was associated with Map enhanced intestinal 
inflammation. The rationale for this hypothesis was that acute DSS mediated colitis in the 
BALB/c mouse is defined by a Th1 cytokine profile and because Map infected macrophages 
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is capable of producing a similar profile of cytokines.[10, 11] To address our goals, we 
analyzed adaptive and innate intestinal and systemic cytokine expression patterns and 
evaluated mice for Map antigen specific antibody. We infected a subset of SCID/C.B-17 
(SCID) mice with Map to determine if enhanced intestinal disease would occur in the 
absence of an adaptive immune response. 
Our results confirm that Map infected mice had antigen specific production of 
adaptive immune cytokines, namely IFNγ and IL-17, in addition to the production of antigen 
specific IgG2a and IgG1 antibody. However, we observed enhanced activation of the innate 
rather than adaptive immune response Map infected BALB/c mice treated with DSS. An 
innate mechanism was supported by infecting SCID mice with Map followed by DSS 
treatment, which resulted in similar clinical disease and mucosal pathology. A common 
feature of the disease in both BALB/c and SCID mice was increased expression of IL-1β. We 
did not observe an increase in cecal IFNγ, IL-17 or IL-4, nor did we observe Map antigen 
specific production of these cytokines in lymphoid cells isolated from the cecal tonsil of 
BALB/c mice infected with Map and treated with DSS.  
Although Map infected and DSS treated SCID and BALB/c mice had a similar 
clinical phenotype and had increased expression of IL-1β, there were differences identified 
between these two mouse strains. Ceca from Map infected SCID mice had increased 
expression of TNF-α which was dependent on exposure to DSS. Similar to the BALB/c mice, 
there was also increased expression of caspase-1 in SCID Map-infected and DSS-treated 
mice; however, caspase-1 expression was greater in DSS only treated SCID mice. This may 
reflect differences in the character of the lesions, for example the rate of apoptosis or 
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temporal variations in caspase-1 expression in the two groups of mice.[12] In total, the 
results from this study indicate that Map infection primes the mucosa for secretion of innate 
cytokines. 
Persistent mycobacterial infection sensitizes macrophages to a pro-inflammatory    
phenotype following intestinal epithelial injury  
 
The results from Chapter 3 indicated that Map mediated enhanced intestinal disease 
was not dependent on the adaptive immune response, but was associated with increased 
activation of the innate immune response; more specifically, increased IL-1β. In Chapter 4, 
we set out to understand how Map infection in the context of acute mucosal injury, promotes 
an augmented innate immune profile. Because Map infection was limited to mucosal 
macrophages, we focused our studies on macrophages as a key source of inflammatory 
cytokines. To accomplish our goal, we chose to define how Map infection alters macrophage 
activation phenotype and influences expression of IL-1β. We analyzed both in vivo and in 
vitro IL-1β protein expression in Map infected macrophages and assessed the ability of Map 
to mediate inflammasome IL-1β production. Based on the in vitro ability of Map to induce 
the expression of IL-1β in mouse macrophages, we hypothesized that Map infected 
macrophages would have an increase in both the expression and secretion of IL-1β.[11, 13] 
To evaluate the functional phenotype of Map infected macrophages, we examined the 
expression of iNOS; a marker associated with classic activation and enhanced killing of 
intracellular pathogens, and arginase, an enzyme characteristic of alternative activation and 
wound-healing macrophages.[14, 15] We hypothesized that there would be minimal iNOS 
expression relative to arginase which would be expected to be increased since Map infected 
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macrophages do not characteristically express iNOS and because SCID macrophages are 
prone to express arginase.[16-18] An additional aim was to determine if Map enhanced 
intestinal lesions contained increased numbers of macrophages. By immunohistochemistry, 
Map infected macrophages had similar expression of pro-IL-1β that was not affected by DSS 
treatment. However, macrophages infected with Map and exposed in vitro to LPS had 
augmented IL-1β production which was not dependent on the NALP3 inflammasome. Map 
infected and DSS treated mice also had increased iNOS expression and greater numbers of 
F4/80+ cells. iNOS expression was not identified in non-infected macrophages. In summary, 
these observations indicate that Map infection promotes a basal level of IL-1β production 
thereby priming macrophage for IL-1β enhanced secretion following interaction with a 
second stimulus, namely, LPS.  
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Proposed model for Map enhanced intestinal injury  
The results from this thesis support the following model (Figure 1) where Map 
infection of intestinal macrophages promotes a basal level of IL-1β and iNOS expression 
thereby priming macrophages for enhanced production of these molecules following 
interaction with a second stimulus, namely, LPS, from the intestinal lumen. Mechanistically, 
IL-1β may compound DSS-mediated injury through disruption of tight junctions via up-
regulation of myosin light chain kinase, while increased iNOS expression may be associated 
with free radical mediated injury following the formation of reactive nitrogen intermediates 
such as NO2-, NO3- and ON00- or as an immunomodulator.[19]  Moreover, these effects may 
be further augmented by Map-mediated increases in the total number of macrophages 
recruited to sites of intestinal inflammation.    
  
 
     Enhanced injury 
Disruption of tight 
junctions (myosin light 
chain kinase) 
Free radical injury 
Figure 1 
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Recommendations for Future Research 
Our observations suggest that Map enhanced activation of the innate immune system 
can sensitize the mucosa to DSS mediated inflammation.  This is based on the observation of 
increased IL-1β expression in both BALB/c and SCID mice which had a similar disease 
phenotype and the absence of increases in markers of the adaptive immune response. 
Additionally, results from our last set of experiments indicate that Map infection primes 
macrophages for a pro-inflammatory profile after exposure to components of the intestinal 
lumen, such as LPS. Even though these results suggest a mechanism associated with Map 
enhanced intestinal disease, its confirmation requires further research.    
Although we demonstrated increased IL-1β mRNA expression by qRT-PCR, it would 
be critical to confirm that there is a corresponding increase in IL-1β protein levels. This could 
be accomplished measuring IL-1β secretion in colonic explants. To validate that IL-1β plays 
a central role in the pathogenesis of our model it would also be important to block IL-1β with 
a monoclonal antibody or disrupt its binding to target cells, with the hypothesis that disease 
would be ameliorated. Alternatively, to substantiate that IL-1β producing macrophages are 
key effector cells in our model, these cells could be isolated from Map infected ceca, 
expanded in vitro and transferred to SCID mice to determine if enhanced disease occurred 
following DSS treatment. It would also be important to neutralize TNF-α since this cytokine 
was increased, in conjunction with IL-1β, in our SCID mouse model of Map enhanced 
disease.   
If IL-1β is shown to be essential for enhanced disease, a more precise mechanism for 
IL-1β enhanced disease could be explored. IL-1β is capable of altering intestinal permeability 
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via activation of NF- κβ which results in an increase in the expression of myosin light chain 
kinase (MLCK).[20, 21] Increased MLCK phosphorylates myosin II regulatory light chain 
(MLC) which promotes opening of the tight junction via contraction of peri-junctional actin-
myosin filaments. [22-24] An in vitro transwell system could be used evaluate this possibility 
by placing Map infected macrophages in one well and intestinal epithelial cells in an adjacent 
chamber and then assess if MLCK expression is enhanced. If it is, then an IL-1β antibody 
could be used to confirm that IL-1β mediates this change.  
There may be multiple mechanisms responsible for enhanced IL-1β in Map infected 
and DSS treated mice. Map infected macrophages may have indirectly mediated this increase 
in IL-1β through increased recruitment of neutrophils, which are able to produce IL-1β 
following exposure to LPS.[25] We observed a semi-quantitative increase in cecal lesion 
associated neutrophils in Map infected and DSS treated mice (data not shown). By analogy, 
Mycobacterium tuberculosis infected mouse macrophages are capable of recruiting 
neutrophils via the production of KC, a neutrophil chemoattractant.[26] We could isolate 
Map infected macrophages from the intestines or infect macrophages in vitro to determine if 
they had increased production of KC. Map infected macrophages may have also had 
increased expression of TLR receptors, such as TLR4, which has been shown in the ileum of 
Map infected sheep.[27] Enhanced TLR expression on Map infected macrophages could 
amplify the pro-inflammatory response following exposure to LPS which itself can increase 
both the expression and activation of caspase-1 and IL-1β.[28-30] This possibility could be 
evaluated by examining TLR expression by immunohistochemistry or flow cytometry on in 
vitro or in vivo Map infected macrophages.  
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Although the results from our experiments support a role for excessive activation of 
the innate immune system; in particular increased IL-1β, as a cause for the Map enhanced 
intestinal inflammation, it is not possible to rule-out the existence of more important or at 
least contributory mechanisms in our model. There was a difference in intestinal bacterial 
load between SCID and BALB/c mice, with greatest numbers of Map being present in SCID 
mice. Although there was this difference in bacterial burden, Map infected and DSS treated 
SCID and BALB/ c mice had the same disease phenotype, suggesting that there may be 
alternative adaptive or regulatory immune mechanisms involved in the BALB/c mouse 
model of enhanced intestinal disease. The relatively small number of Map infected cells in 
BALB/c mice was often present in the cecal tonsil or gut associated lymphoid tissue, 
implying that Map altered the adaptive immune response; however, we did not identify 
increases in markers of the adaptive immune response in the cecum. With that said, it would 
be beneficial to assess the immune response in the mesenteric lymph nodes, with the 
hypothesis being that cells from this site would have a similar cytokine profile to that in the 
cecum.  
We did not extensively evaluate the humoral immune response. Map infection in DSS 
treated BALB/c mice may have been associated with an enhanced humoral immune response 
to the intestinal flora.  Aberrant host immune responses to the intestinal flora have been 
demonstrated in a Helicobacter bilis model of intestinal inflammation and in a subclinical 
CMV model of enhanced intestinal disease.[3, 31] To answer this question we could evaluate 
serum for antibodies reactive to the intestinal flora, with the greatest titers presumably being 
present in Map infected and DSS treated mice. If a population of intestinal flora reactive B-
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cells were identified, these cells could be transferred into SCID mice to determine if they 
exacerbated DSS mediated disease. Alternatively, a population of CD4+CD25+ regulatory T-
cells may have been generated which then persisted when Map bacterial loads were reduced. 
Antigen specific regulatory T-cells have been demonstrated in bovine paratuberculosis and 
persistence of regulatory T-cells in the presence of low antigen has been demonstrated 
previously.[32, 33] Loss of regulatory T-cell function in a model of enhanced intestinal 
disease has been described. For example, a previous study in a SAMP1/YitFc mouse model 
of ileitis demonstrated that B-cells are associated with exacerbation of intestinal 
inflammation, which is not antibody dependent. These authors demonstrated that mesenteric 
lymph node B-cell numbers correlated with the severity of ileitis and that B-cells mediated 
enhanced intestinal inflammation by interfering with regulatory T-cell function. [34]  To 
examine this possibility, we could quantify the number of T-regulatory cells and assess if 
there was expansion of B-cells in the cecal mucosa or mesenteric lymph nodes. The 
hypothesis would be that B-cell proliferation in the mesenteric lymph node would correlate 
with increased disease severity in Map infected and DSS treated mice and correspond with a 
decrease in number or functioning of regulatory T-cells.  
Additional unanticipated results could be further investigated with in vitro Map 
infected and LPS stimulated macrophages. We observed increased iNOS in Map infected 
and DSS treated mice. One plausible explanation for the increase in iNOS is that 
superimposed exposure to intestinal antigens, such as LPS, enhanced expression of 
iNOS.[35] The augmented iNOS levels may also be partially explained by the increases in 
IL-1β.[36] Exposure of Map infected macrophages to LPS and/or IL-1β would be expected 
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to increase nitric oxide. To further confirm that increased iNOS is associated with enhanced 
disease in our model, nitric oxide levels in colonic explants from Map infected and DSS 
treated mice could be evaluated.  
To further define a mechanism associated with Map and LPS enhanced in vitro 
production of IL-1β, the effect of ATP on enhanced IL-1β secretion could be assessed. We 
would hypothesize that ATP production and its release is increased in Map infected and LPS 
exposed macrophages since endogenously released ATP from LPS exposed macrophages is 
necessary for processing and secretion of IL-1β in vitro.[37] Presumably, since Map is also 
a TLR agonist, this response would be further augmented in Map infected and LPS treated 
macrophages.[38]  To evaluate the importance of ATP, we could we could utilize ATPase to 
determine if enhanced IL-1β secretion is abolished by the elimination of ATP. Lastly, Map 
and LPS associated increases in IL-1β were not significantly affected in NALP3 knockout 
macrophages. However, ASC was necessary for increased IL-1β; ASC is associated with the 
NALP1/2 inflammasome.[39]  Therefore, future studies utilizing macrophages deficient in 
these inflammasome proteins could be performed to determine if they are critical for Map 
mediated production of IL-1β.  
There were decreased numbers of Map in the small intestines of DSS treated BALB/c 
mice which may be due to an enhanced non-specific immune response induced by DSS. It 
has been shown that DSS-pulsed macrophages promote the proliferation of T-cells from 
colitic mice.[40] Additional immunohistochemical studies could be performed to define the 
activation status of Map infected BALB/c macrophages; with the hypothesis that Map 
infected macrophages in DSS treated BALB/c mice would have enhanced expression of 
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iNOS. It is also possible that DSS had a direct inhibitory effect on Map replication, which 
could be evaluated in Map infected macrophages in vitro. 
Since F4/80 positive cells were elevated in Map infected and DSS treated mice, it 
would be interesting to assess the impact of preventing recruitment of macrophages to sites 
of DSS mediated inflammation. The hypothesis would be that Map enhanced DSS intestinal 
inflammation would be ameliorated by preventing infiltration of this population of cells, but 
not completely abolished since Map infected macrophages alone appear to have an enhanced 
pro-inflammatory profile which could promote intestinal inflammation. Furthermore, since 
increased numbers of F4/80 positive cells appeared to be associated with cecal crypt 
epithelium, the role of macrophages in the proliferative or repair response in DSS mediated 
intestinal injury could be assessed since it has been shown that crypt epithelial associated 
activated macrophages play an important role in the reparative response following DSS 
mediated intestinal injury.[41] Similar studies to those performed Chapters 2 and 3 could be 
performed, but after 6 days of DSS treatment, administer water for a period of a few weeks to 
allow for repair to occur. 
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